[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 227
1. Forman SJ: What is the role of reduced-intensity transplantation in the treatment of older patients with AML? Hematology Am Soc Hematol Educ Program; 2009;:406-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the role of reduced-intensity transplantation in the treatment of older patients with AML?
  • Acute myelogenous leukemia (AML), either de novo or arising out of antecedent myelodysplasia, increases with age and is rarely curable by standard treatments used for younger patients.
  • Although those patients who undergo transplant in a first remission often do well, the vast majority of older patients have not benefited because of the low successful remission achieved with standard therapy, the delay in initiating a donor search, and the lack of significant benefit from transplantation in patients who are not in remission.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008226.001).
  • [ISSN] 1520-4383
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  • [Number-of-references] 32
  •  go-up   go-down


2. Rowe JM: Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)? Leukemia; 2005 Aug;19(8):1324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)?
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Age Factors. Aged. Disease-Free Survival. Humans. Middle Aged. Prospective Studies. Remission Induction. Survival Rate


3. Huang M, Li C, Liang H, Zhou J, Deng J, Liu W: Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 chromosomal translocation in hematologic malignancies. J Huazhong Univ Sci Technolog Med Sci; 2006;26(6):661-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiplex reverse transcription-polymerase chain reaction (M-RT-PCR) has been proved to possess great clinical potential for simultaneous screening of 29 chromosomal translocations in acute leukemia.
  • To evaluate the clinical value of M-RT-PCR in hematologic malignancies, bone marrow samples from 90 patients with various hematologic malignancies, including 25 acute myelogenous leukemia (AML), 22 acute lymphoblastic leukemia (ALL), 27 chronic myelogenous leukemia (CML), 4 myeloproliferative diseases (MPD), 3 chronic lymphoblastic leukemia (CLL), 3 non-Hodgkin's lymphoma (NHL), 3 myelodysplastic syndrome (MDS), 2 multiple myeloma (MM) and 1 malignant histiocytosis (MH) were subjected to both M-RT-PCR and chromosome karyotypic analysis.
  • Some of cases were subjected to follow-up examination of M-RT-PCR during the period of clinical complete remission (CR) for detection of minimal residual leukemia.
  • Furthermore, M-RT-PCR had also shown good clinical relevance when used as an approach to detect minimal residual leukemia.
  • We concluded that M-RT-PCR could be used as an efficient and fast diagnostic tool not only in the initial diagnosis of hematologic malignancies but also in subsequent monitor of minimal residual leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1998 Jul 15;92(2):574-88 [9657758.001]
  • [Cites] Leukemia. 1996 May;10(5):788-94 [8656673.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2004 Jul;25(7):413-6 [15355694.001]
  • [Cites] Am J Hematol. 2002 Jan;69(1):80-2 [11835339.001]
  • [Cites] Blood. 1992 Jun 1;79(11):2990-7 [1586743.001]
  • [Cites] Zhonghua Xue Ye Xue Za Zhi. 2003 May;24(5):256-8 [12859878.001]
  • (PMID = 17357482.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Nagai S, Nannya Y, Takahashi T, Kurokawa M: Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia. Ann Hematol; 2010 Jul;89(7):741-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19904535.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


5. Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K: Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant; 2005 Feb;11(2):122-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
  • Allogeneic stem cell transplantation (ASCT) has improved the outcome of acute myelogenous leukemia (AML).
  • To further improve the treatment outcome of ASCT in AML, finding a modifiable prognostic factor is mandatory.
  • We evaluated the effect of CD34(+) cell dose on survival in allogeneic bone marrow transplantation (BMT) from HLA-matched sibling donors for AML patients in first complete remission (CR1).
  • The high CD34(+) cell dose patients had better overall survival (5-year overall survival rate, 75% +/- 6% vs 52% +/- 9%; P = .01) and leukemia-free survival (5-year leukemia-free survival rate, 70% +/- 6% vs 44% +/- 9%; P = .04).
  • CD34(+) cell dose was the only independent prognostic factor in overall survival and leukemia-free survival.
  • There were no differences in the engraftment of neutrophil and platelet, grade II-IV acute graft-versus-host disease (GVHD), extensive-stage chronic GVHD, and transplant-related mortality between the high and low CD34(+) cell dose groups.
  • We confirmed that high CD34(+) cell dose favorably affects the outcomes in allogeneic BMT for AML.
  • The effort to attain a high CD34(+) cell dose should be pursued during bone marrow harvest in allogeneic BMT for AML in CR1.
  • [MeSH-major] Antigens, CD34 / analysis. Bone Marrow Cells / cytology. Bone Marrow Transplantation. Leukemia, Myeloid, Acute. Tissue Donors


6. Grant R, Keidan J: False positive Kleihauer results: an unusual cause in a postnatal patient in remission from acute myeloid leukaemia. Int J Lab Hematol; 2009 Apr;31(2):241-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False positive Kleihauer results: an unusual cause in a postnatal patient in remission from acute myeloid leukaemia.
  • A 34-year-old woman, in remission from acute myeloid leukaemia, had a positive postnatal Kleihauer result.
  • Hereditary persistence of foetal haemoglobin was excluded as a Kleihauer test performed in a pregnancy prior to the development of leukaemia was negative.
  • In this case, the patient was confirmed to be in a true molecular remission from leukaemia and yet appeared to have a residual clonal population of HbF erythrocytes; the significance of this finding remains unclear.
  • [MeSH-major] Fetal Hemoglobin / analysis. Hemoglobin A2 / analysis. Leukemia, Myeloid, Acute / blood. Neoplasm Regression, Spontaneous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267811.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9034-53-1 / Hemoglobin A2; 9034-63-3 / Fetal Hemoglobin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


7. Reikvam H, Hatfield KJ, Oyan AM, Kalland KH, Kittang AO, Bruserud O: Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. Eur J Haematol; 2010 Mar;84(3):239-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
  • OBJECTIVES: Angiogenesis seems important for both leukemogenesis and chemosensitivity in acute myelogenous leukemia (AML).
  • We investigated the constitutive release of MMPs and TIMPs for a large group of consecutive AML patients.
  • METHODS: AML cells were cultured in vitro either alone or together with microvascular endothelial cells, and levels of MMPs and TIMPs were determined in culture supernatants.
  • RESULTS: AML cells showed constitutive release of several MMPs and TIMPs.
  • MMP-9 release was higher for AML cells with monocytic differentiation corresponding to the FAB-subtype M4/M5 AML; it was mainly released in its inactive form, but endogenously active MMP-9 could be detected even in the presence of the constitutively released TIMP-1/2.
  • Endothelial cells released relatively high levels of MMP-10, and these levels were further increased by coculture with AML cells.
  • Patients achieving complete hematological remission after only one induction cycle showed relatively low constitutive MMP-2 release.
  • CONCLUSION: We conclude that primary human AML cells show constitutive release of both MMPs and TIMPs, and this release may be important for leukemogenesis and possibly also for chemosensitivity.
  • [MeSH-major] Leukemia, Myeloid / pathology. Matrix Metalloproteinases / secretion. Neoplasm Proteins / secretion. Tissue Inhibitor of Metalloproteinases / secretion
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Angiopoietin-2 / pharmacology. Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / pharmacology. Bortezomib. Cells, Cultured / cytology. Chemokines / secretion. Coculture Techniques. Culture Media, Serum-Free / pharmacology. Cytarabine / administration & dosage. Diterpenes / pharmacology. Endothelial Cells / cytology. Female. Humans. Imidazoles / pharmacology. Male. Matrix Metalloproteinase Inhibitors. Middle Aged. NF-kappa B / antagonists & inhibitors. Protease Inhibitors / pharmacology. Pyrazines / pharmacology. Quinoxalines / pharmacology. Receptor, TIE-2 / antagonists & inhibitors. Receptor, TIE-2 / physiology. Recombinant Proteins / pharmacology. Tumor Cells, Cultured / enzymology. Tumor Cells, Cultured / secretion

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922462.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-ingenyl angelate; 0 / 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline; 0 / Angiopoietin-2; 0 / Anthracyclines; 0 / Boronic Acids; 0 / Chemokines; 0 / Culture Media, Serum-Free; 0 / Diterpenes; 0 / Imidazoles; 0 / Matrix Metalloproteinase Inhibitors; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / Quinoxalines; 0 / Recombinant Proteins; 0 / Tissue Inhibitor of Metalloproteinases; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; EC 2.7.10.1 / Receptor, TIE-2; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


8. Anderson GA, Braaten K: Prostatic extramedullary leukemia as a first site of relapse of acute nonlymphocytic leukemia. Urol Oncol; 2005 Nov-Dec;23(6):419-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic extramedullary leukemia as a first site of relapse of acute nonlymphocytic leukemia.
  • Extramedullary leukemia (EML) is an uncommon clinical diagnosis in patients with acute nonlymphocytic leukemia (ANLL).
  • Prostatic EML as a first site of ANLL relapse is even more rare.
  • We describe an additional case of prostatic EML as a site of ANLL relapse.
  • An asymptomatic male in ANLL remission was found to have a normal prostate-specific antigen (PSA) and a myeloid leukemic infiltrate in a newly diagnosed prostate nodule.
  • Staging was negative for ANLL relapse.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local / pathology. Prostatic Neoplasms / pathology. Prostatic Neoplasms / secondary


9. Moon HW, Shin S, Kim HY, Kim YR, Cho HI, Yoon SS, Park S, Kim BK, Chun H, Kim HC, Park CJ, Min YH, Lee DS: Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia. Leukemia; 2006 Aug;20(8):1408-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
  • We have experienced a number of cases of AML1/ETO+ acute myelogenous leukemia that showed remission based on bone marrow (BM) morphological criteria, but that revealed clonal abnormalities in most cells by fluorescence in situ hybridization (FISH).
  • Interestingly, most of these cases had AML with AML1/ETO rearrangement.
  • To clarify the possible mechanisms underlying this phenomenon, we investigated the expression levels of G-CSFR in AML cells with AML1/ETO rearrangement by flow cytometry and real-time polymerase chain reaction (PCR).
  • The number of AML1/ETO+ cells expressing G-CSFR at baseline was significantly higher than that of AML1/ETO- AML cells (2673 vs 522).
  • This study reveals that cases showing remission after treatment with G-CSF mostly had leukemia with AML1/ETO rearrangement.
  • We recommend that remission should be confirmed by FISH, because malignant clones can be differentiated and masked in morphological examination or chromosome test, especially for AML with AML1/ETO rearrangement.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Rearrangement. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791271.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


10. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC: Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res; 2008 Mar 1;14(5):1446-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia.
  • PURPOSE: Proteasome inhibition results in cytotoxicity to the leukemia stem cell in vitro.
  • We conducted this phase I study to determine if the proteasome inhibitor bortezomib could be safely added to induction chemotherapy in patients with acute myelogenous leukemia (AML).
  • Nine patients had relapsed AML (ages, 18-59 years, n = 4 and > or = 60 years, n = 5).
  • There were 22 patients of > or = 60 years with previously untreated AML (eight with prior myelodysplasia/myeloproliferative disorder or cytotoxic therapy).
  • Overall, 19 patients (61%) achieved complete remission (CR) and three had CR with incomplete platelet recovery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Leukemia, Myeloid, Acute / metabolism

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316568.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA066996
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Boronic Acids; 0 / Pyrazines; 04079A1RDZ / Cytarabine; 69G8BD63PP / Bortezomib; ZRP63D75JW / Idarubicin
  •  go-up   go-down


11. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk Kooy M, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Lowenberg B: Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood; 2007 May 1;109(9):3658-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
  • The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison.
  • We evaluated our results and those of the previous MRC, BGMT, and EORTC studies in a meta-analysis, which revealed a significant benefit of 12% in overall survival (OS) by donor availability for all patients with AML in CR1 without a favorable cytogenetic profile.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Living Donors. Transplantation Conditioning


12. Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA: Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother; 2010 Jul;65(7):1466-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
  • BACKGROUND: Large randomized controlled trials have shown significant decreases in morbidity and mortality in leukaemia patients with posaconazole prophylaxis.
  • METHODS: We prospectively evaluated the epidemiology of IFDs in acute myelogenous leukaemia (AML) patients undergoing first remission-induction chemotherapy before and after posaconazole prophylaxis had been introduced as a standard of care.
  • CONCLUSIONS: After introduction of posaconazole prophylaxis for patients with AML, the number of febrile days, the incidence rate of IFDs and aspergillosis and the duration of hospitalization decreased significantly.
  • [MeSH-major] Antifungal Agents / therapeutic use. Chemoprevention / methods. Leukemia, Myeloid, Acute / complications. Mycoses / prevention & control. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20410061.001).
  • [ISSN] 1460-2091
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Polyenes; 0 / Triazoles; 6TK1G07BHZ / posaconazole
  •  go-up   go-down


13. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD: Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4467-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
  • In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%.
  • We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML.
  • Complete remissions (CR) were achieved in 12 of 15 (75%) newly diagnosed secondary AML, 18 of 24 (75%) first relapse after short CR (median CR, 9 months, including prior allotransplant), and 2 of 13 (15%) primary refractory but 0 of 10 multiply refractory AML.
  • CONCLUSIONS: Flavopiridol has anti-AML activity directly and in combination with ara-C and mitoxantrone.
  • This timed sequential regimen induces durable CRs in a significant proportion of adults with newly diagnosed secondary AML (including complex cytogenetics) and adults with AML in first relapse after short first CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Cytarabine / administration & dosage. Disease-Free Survival. Female. Flavonoids / administration & dosage. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Piperidines / administration & dosage. Prognosis. Remission Induction. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671131.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


14. Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G: Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant; 2006 Apr;12(4):466-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
  • The optimal postremission treatment for elderly patients with acute myelogenous leukemia (AML) is presently unknown, but recent studies report the feasibility of autologous stem cell transplantation in this population.
  • To better understand the long-term outcome of autologous transplantation in AML patients > or =60 years of age, we evaluated high-dose chemoradiotherapy preparative conditioning followed by transplantation of peripheral blood progenitor cells procured after a single cycle of cytarabine-based consolidation chemotherapy as postremission therapy in 27 patients aged 60 to 71 years (median age, 65 years) with newly diagnosed AML in first complete remission (CR).
  • The median follow-up from remission for surviving patients was 81 months (range, 41.4-123.1 months).
  • Leukemia-free survival and overall survival are 10.3 and 13.4 months, respectively.
  • Actuarial leukemia-free and overall survival at 3 years are 25% +/- 9% and 28% +/- 9%, respectively.
  • Our results demonstrate that autologous transplantation of peripheral blood progenitor cells is well tolerated and feasible for patients > or =60 years of age with AML in first CR.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Aged. Cytarabine / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Recurrence. Remission Induction. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545730.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine
  •  go-up   go-down


15. Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglunds M, Karlsson K, Stockelberg D, Wahlin A, Aström M, Arnesson C, Brunell-Abrahamsson U, Carstensen J, Fredriksson E, Holmberg E, Nordenskjöld K, Wiklund F, Swedish Adult Acute Leukemia Registry Group: Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia; 2006 Jan;20(1):42-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
  • Combination chemotherapy may induce remission from acute myeloid leukemia (AML), but validated criteria for treatment of elderly are lacking.
  • The remission intention (RI) rate for elderly patients, as reported to the Swedish Leukemia Registry, was known to be different when comparing the six health care regions, but the consequences of different management are unknown.
  • The Leukemia Registry, containing 1672 AML patients diagnosed between 1997 and 2001, with 98% coverage and a median follow-up of 4 years, was completed with data from the compulsory cancer and population registries.
  • Among 506 treated and untreated patients aged 70-79 years with AML (non-APL), there was a direct correlation between the RI rate in each health region (range 36-76%) and the two-year overall survival, with no censored observations (6-21%) (chi-squared for trend=11.3, P<0.001; r2=0.86, P<0.02, nonparametric).
  • Differences could not be explained by demographics, and was found in both de novo and secondary leukemias.
  • Survival of 70-79-year-old AML patients is better in regions where more elderly patients are judged eligible for remission induction.
  • [MeSH-major] Attitude of Health Personnel. Leukemia, Myeloid / drug therapy. Patient Selection
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Follow-Up Studies. Humans. Middle Aged. Registries. Remission Induction. Survival Rate. Sweden / epidemiology. Treatment Outcome


16. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S: Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol; 2010 Apr 10;28(11):1878-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
  • PURPOSE Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) primarily afflict older individuals.
  • To define prognostic factors impacting long-term outcomes of RIC regimens in patients older than age 40 years with AML in first complete remission or MDS and to determine the impact of age, we analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR).
  • Outcomes analyzed included neutrophil recovery, incidence of acute or chronic graft-versus-host disease (GVHD), nonrelapse mortality (NRM), relapse, disease-free survival (DFS), and overall survival (OS).
  • RESULTS Univariate analyses demonstrated no age group differences in NRM, grade 2 to 4 acute GVHD, chronic GVHD, or relapse.
  • Patients age 40 to 54, 55 to 59, 60 to 64, and > or = 65 years had 2-year survival rates as follows: 44% (95% CI, 37% to 52%), 50% (95% CI, 41% to 59%), 34% (95% CI, 25% to 43%), and 36% (95% CI, 24% to 49%), respectively, for patients with AML (P = .06); and 42% (95% CI, 35% to 49%), 35% (95% CI, 27% to 43%), 45% (95% CI, 36% to 54%), and 38% (95% CI, 25% to 51%), respectively, for patients with MDS (P = .37).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Remission Induction. Survival Rate. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome


17. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR: Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia; 2010 Apr;24(4):699-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia.
  • This phase 1 study examined the maximum-tolerated dose (MTD), safety and pharmacokinetic/pharmacodynamic profiles of alvespimycin in patients with advanced acute myeloid leukemia (AML).
  • Patients with advanced AML received escalating doses of intravenous alvespimycin (8-32 mg/m(2)), twice weekly, for 2 of 3 weeks.
  • Antileukemia activity occurred in 3 of 17 evaluable patients (complete remission with incomplete blood count recovery).
  • The twice-weekly administered alvespimycin was well tolerated in patients with advanced AML, showing linear pharmacokinetics, target inhibition and signs of clinical activity.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzoquinones / administration & dosage. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20111068.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP70 Heat-Shock Proteins; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  •  go-up   go-down


18. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, Wallhult E, Hellstrand K: Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood; 2006 Jul 1;108(1):88-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
  • The primary objective of this phase 3 study was to determine whether postconsolidation immunotherapy with interleukin-2 (IL-2) and histamine dihydrochloride (HDC) improved the leukemia-free survival (LFS) of adult patients with acute myeloid leukemia (AML) in complete remission (CR).
  • Three hundred twenty patients with AML (median age, 57 years; range, 18-84 years) were stratified by CR1 or subsequent CR (CR > 1) and randomly assigned to treatment with HDC/IL-2 or no treatment (control).
  • Study arms were balanced for age, sex, previous treatment, leukemic karyotypes, time from CR to inclusion, and frequency of secondary leukemia.
  • These results indicate that HDC/IL-2 treatment offers an efficacious and tolerable treatment for patients with AML in remission.
  • [MeSH-major] Histamine / therapeutic use. Immunotherapy. Interleukin-2 / therapeutic use. Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Recurrence. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. HISTAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556892.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 820484N8I3 / Histamine
  •  go-up   go-down


19. Xu WL, Shen HL, Ao ZF, Chen BA, Xia W, Gao F, Zhang YN: Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res; 2006 Apr;30(4):407-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia.
  • The potential mechanism of the chemotherapy resistance in acute myeloid leukemia (AML) is the multidrug resistance (MDR-1) gene product P-glycoprotein (P-gp), which is often overexpressed in myeloblasts from acute myeloid leukemia.
  • In a multicenter clinical trial, 38 patients with poor risk forms of AML were treated with tetrandrine (TET), a potent inhibitor of the MDR-1 efflux pump, combined with daunorubicin (DNR), etoposide and cytarabine (TET-DEC).
  • Sixteen patients (42%) achieved complete remission or restored chronic phase, 9 achieved partial remission (PR) and 13 failed therapy.
  • However, there was no difference in DNR uptake between responding and non-responding patients.
  • Our data showed that TET-DEC was relatively well tolerated in these patients with poor risk AML, and had encouraging antileukemic effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219352.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Benzylisoquinolines; 0 / P-Glycoprotein; 04079A1RDZ / Cytarabine; 29EX23D5AJ / tetrandrine; 6PLQ3CP4P3 / Etoposide; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


20. Sharma S, Pati HP: Erythrocyte enzyme abnormalities in leukemias. J Assoc Physicians India; 2006 Jun;54:453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Red cell enzymes were assayed in a total of 67 patient including 24 patients with AML (19 relapse, 5 remission), 16 patients with ALL (10 relapse, 6 remission), 22 patients with CML and 5 patients with blastic CML.
  • Diagnosis of leukemia was based on clinical presentation, peripheral blood smear and bone marrow examination (as per FAB classification).
  • Red cell HK was high in all leukemia subtypes.
  • Notably there was no PK deficiency in AML or G6PD deficiency in ALL.
  • Activities of G6PD and PK could be correlated in cases of CML, AML, (p<0.05) and ALL (p<0.01) i.e. when there was increased activity of G6PD, PK activity also tended to be higher.
  • HK activity showed a positive correlation with PK and G6PD activity in cases of CML (p<0.05), however in acute leukemia there was no such correlation.
  • Alteration of enzyme activities among red cells in leukemia occurred only during relapse.
  • At the time of remission there has been no significant alteration in any of the enzyme activities.
  • It would therefore, appear that enzyme alterations seen in leukemia patients is due to abnormal pluripotent stem cell that has given to a leukemia cell.
  • With the recovery of normal stem cells function during remission, enzyme abnormalities tend to become normal.
  • [MeSH-major] Erythrocytes, Abnormal / metabolism. Leukemia / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology. Leukemia, Myeloid, Acute / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology. Remission Induction. Risk Factors

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909693.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  •  go-up   go-down


21. Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E: Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res; 2008 May 15;14(10):3077-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
  • PURPOSE: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features.
  • Such patients might benefit from additional therapy in complete remission (CR).
  • Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML.
  • We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR.
  • Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with secondary AML and adverse cytogenetics.
  • CONCLUSIONS: This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1964-70 [17581608.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):672-80 [12760285.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3880-9 [12920034.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):418-23 [15813916.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2480-9 [16735702.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1387-94 [17082323.001]
  • [Cites] Blood. 2007 May 15;109(10):4158-63 [17264294.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]
  • (PMID = 18483374.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 69854; United States / NCI NIH HHS / CA / U01 CA069854-07; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / U01 CA070095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib
  • [Other-IDs] NLM/ NIHMS281726; NLM/ PMC3074480
  •  go-up   go-down


22. Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U: Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. Leuk Res; 2009 Sep;33(9):1189-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
  • Cytogenetic findings at diagnosis have influence on prognosis in patients with acute myelogenous leukaemia (AML) or MDS who undergo induction chemotherapy.
  • Assessment of remission and treatment decisions are based on cytological findings.
  • We analyzed the prognostic impact of cytogenetic remission status in 118 patients with abnormal karyotype who received induction chemotherapy.
  • Eighty-three patients achieved complete remission (CR) and 20 achieved partial remission.
  • Median survival (excluding patients with AML M3) of the CCR group was 37 months, as compared to 11 months in patients with persistence of abnormal karyotype (p < 0.0001).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Remission Induction


23. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W: NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol; 2010 Feb 20;28(6):955-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
  • PURPOSE To conduct a pilot study to determine the safety, feasibility, and engraftment of haploidentical natural killer (NK) cell infusions after an immunosuppressive regimen in children with acute myeloid leukemia (AML).
  • PATIENTS AND METHODS Ten patients (0.7 to 21 years old) who had completed chemotherapy and were in first complete remission of AML were enrolled on the Pilot Study of Haploidentical Natural Killer Cell Transplantation for Acute Myeloid Leukemia (NKAML) study.
  • With a median follow-up time of 964 days (range, 569 to 1,162 days), all patients remain in remission.
  • We propose to further investigate the efficacy of KIR-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increasing mortality in children with AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy. Killer Cells, Natural / transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy


24. Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, Tanizawa Y: Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med; 2010 Feb;220(2):121-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.
  • Gemtuzumab ozogamicin (GO) is a recombinant humanized monoclonal antibody, conjugated to calicheamicin, which targets the CD33 antigen that is expressed in acute myelogenous leukemia (AML) blasts.
  • The selectivity of GO for CD33-positive leukemic cells makes it an attractive agent for use in patients with multiple sites of IEMR after allo-HSCT, because GO does not suppress cells responsible for the putative graft-versus-leukemia (GVL) effect.
  • Herein, we describe a 54-year-old male patient who developed AML with multiple sites of extramedullary (EM) relapse after allo-HSCT, and who exhibited apparent donor-derived hematopoiesis in the bone marrow.
  • A biopsy specimen from a lumbar soft tissue mass confirmed EM relapse, and revealed that donor T lymphocytes were present in the relapse site and that leukemic cells expressed CD33.
  • He achieved complete hematological remission, and has remained in remission, with only mild liver injury, for more than 10 months since GO treatment.
  • GO can be an effective therapy for IEMR after allo-HSCT, especially when cytotoxic T lymphocytes react to leukemic cells at the site of EM relapse.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Sarcoma, Myeloid / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bone and Bones / radionuclide imaging. CD8-Positive T-Lymphocytes / pathology. Graft vs Leukemia Effect / immunology. Humans. Leukocytes / metabolism. Leukocytes / pathology. Lumbosacral Region / pathology. Lumbosacral Region / radionuclide imaging. Male. Middle Aged. Peroxidase / metabolism. Recurrence. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139663.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


25. Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML: Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatr Blood Cancer; 2010 Sep;55(3):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study.
  • BACKGROUND: Current event-free survival (EFS) rates for children with newly diagnosed acute myeloid leukemia (AML) approach 50-60%.
  • This report highlights efforts to assess the response rates and survival outcomes after first or greater relapse in children with AML.
  • PROCEDURE: We performed a retrospective cohort review of pediatric patients with relapsed and refractory AML (rAML) previously treated at TACL institutions between the years of 1995 and 2004.
  • Data regarding disease characteristics at diagnosis and relapse, treatment response, and survival was collected on 99 patients and 164 medullary relapses or treatment failures.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Prognosis. Recurrence. Remission Induction. Retreatment. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20658611.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K22 CA113557
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Kondo T, Yasumoto A, Arita K, Sugita J, Shigematsu A, Okada K, Takahata M, Onozawa M, Kahata K, Takeda Y, Obara M, Yamamoto S, Endo T, Nishio M, Sato N, Tanaka J, Hashino S, Koike T, Asaka M, Imamura M: Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. Int J Hematol; 2010 Mar;91(2):310-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.
  • Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy.
  • If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option.
  • Since the efficacy of reduced-intensity stem cell transplantation (RIST) for AML with favorable cytogenetics has not been established, we retrospectively analyzed the outcomes of allo-HSCT in AML patients according to cytogenetic risks.
  • The outcome of allo-HSCT for AML patients with favorable cytogenetics seemed to be superior to that for AML patients with intermediate cytogenetics.
  • In AML patients with favorable cytogenetics, the 3-year overall survival (OS) and relapse-free survival (RFS) rates were 88 and 76%, respectively, in the RIST group.
  • The outcome of RIST for AML patients with favorable cytogenetics was comparable to that for patients who received CST despite the more advanced age and greater organ dysfunction in RIST group than in CST group.
  • Moreover, there was no relapse in patients with favorable cytogenetics who were in hematological remission prior to RIST.
  • Thus, RIST for AML patients with favorable cytogenetics in remission is safe and effective.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods


27. Seiter K, Liu D, Feldman E, Shi Q, Qureshi A, Arshad M, Walia T, Naseer N, Baskind P, Ahmed T: Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution. Leuk Lymphoma; 2006 Mar;47(3):425-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution.
  • This report provides long-term results of the treatment of patients with newly-diagnosed AML with a single high dose of mitoxantrone combined with once daily cytarabine.
  • Patients with a prior antecedent hematologic disorder were eligible.
  • The overall complete remission rate was 64%, with responses in 78% of patients less than 60 years of age and 51% of patients 60 years of age or older.
  • For a sub-set of patients who would be eligible for most US trials, the complete remission rate was 84% in younger patients and 60% in older patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / drug therapy. Mitoxantrone / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cytarabine / administration & dosage. Diagnosis, Differential. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396765.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


28. Gassas A, Ishaqi MK, Afzal S, Finkelstein-Shechter T, Dupuis A, Doyle J: A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center. Bone Marrow Transplant; 2008 Jun;41(11):941-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center.
  • We reviewed 70 consecutive children with AML who received hematopoietic stem cell transplantation (HSCT) in our institution between 1994 and 2005.
  • Expectedly, there was a significant increase in acute GVHD incidence in CR2 patients (40 vs 25% for grades I-II and 30 vs 10% for grades III-IV; P=0.02) and a significant increase in transplant-related mortality (38 vs 11%; P=0.01).
  • Children with relapsed AML who achieve and maintain remission until HSCT, have a reasonable survival, but the outcome of children receiving HSCT in CR1 remains superior.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Hospitals, Pediatric. Humans. Infant. Male. Remission Induction. Retrospective Studies. Transplantation Conditioning. Transplantation, Homologous


29. Okumura H, Yamaguchi M, Kotani T, Sugimori N, Sugimori C, Ozaki J, Kondo Y, Yamazaki H, Chuhjo T, Takami A, Ueda M, Ohtake S, Nakao S: Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings. Eur J Haematol; 2007 Feb;78(2):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
  • Human leukocyte antigen (HLA)-mismatched stem cell transplantation from non-inherited maternal antigen (NIMA)-complementary donors is known to produce stable engraftment without inducing severe graft-versus-host disease (GVHD).
  • We treated two patients with acute myeloid leukemia (AML) and one patient with severe aplastic anemia (SAA) with HLA-mismatched stem cell transplantation (SCT) from NIMA-complementary donors (NIMA-mismatched SCT).
  • Grade III and grade IV acute GVHD developed in patients with AML on day 8 and day 11 respectively, and became a direct cause of death in one patient.
  • [MeSH-major] Anemia, Aplastic / surgery. Blast Crisis / surgery. Chimera / immunology. Graft Rejection / immunology. Graft vs Host Disease / immunology. HLA Antigens / genetics. Immunity, Maternally-Acquired. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Peripheral Blood Stem Cell Transplantation / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Tissue Donors. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cord Blood Stem Cell Transplantation. Disease Progression. Fatal Outcome. Female. Histocompatibility. Humans. Isoantigens / immunology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / pathology. Male. Remission Induction. Siblings. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives


30. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Stewart DA: Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant; 2007 Jul;13(7):814-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
  • A myeloablative conditioning regimen incorporating daily intravenous busulfan, fludarabine, and 400 cGy total-body irradiation was given before allogeneic stem cell transplantation (SCT) to 64 adults with acute leukemia in first and second remission.
  • For 31 matched related (MRD) and 33 alternate donor (AD) SCT the incidence of acute GVHD grade II-IV was 11% +/- 6% versus 35% +/- 9% (P = .047), acute GVHD grade III-IV was 0% versus 10% +/- 6% (P = .09), and chronic GVHD was 40% +/- 9% versus 66% +/- 9% (P = NS), respectively.
  • Projected disease-free (DFS) and overall survival (OS) at 3 years for acute myelogenous leukemia (AML) (n = 36) are the same at 83% +/- 6%, and for acute lymphoblastic leukemia (ALL) (n = 28) are 65% +/- 10% and 78% +/- 8%, respectively.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Stem Cell Transplantation. Transplantation Conditioning
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal / administration & dosage. Antilymphocyte Serum. Antineoplastic Agents / administration & dosage. Busulfan / administration & dosage. Cyclosporine / administration & dosage. Disease-Free Survival. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / administration & dosage. Infusions, Intravenous. Male. Methotrexate / administration & dosage. Middle Aged. Myeloablative Agonists / administration & dosage. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580259.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; 0 / thymoglobulin; 83HN0GTJ6D / Cyclosporine; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


31. Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Kim DW, Lee JW, Park CW, Kim CC: Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. Int J Hematol; 2010 Sep;92(2):342-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
  • To define the role of RIC in AML with old age (>or=55 years) and/or co-morbidities (HCT-CI scores >or=2), we analyzed patients who received allogeneic stem cell transplantation (SCT) with Flu/Bu/TBI 400 cGy/+/-antithymocyte globulin (ATG) conditioning regimen.
  • All patients were in first (n = 25) or second (n = 7) complete remission before undergoing allogeneic SCT.
  • The incidence of acute (grades II-IV) and chronic GVHD by NIH consensus criteria was 34.4 and 62.5%.
  • This study suggests that the Flu/Bu/TBI 400 cGy or Flu/Bu/TBI 400 cGy/ATG-based conditioning regimens maybe a feasible therapeutic approach for AML with old age and/or co-morbidities.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents. Antineoplastic Agents, Alkylating. Comorbidity. Female. Humans. Leukemia, Myeloid, Acute. Male. Middle Aged. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1315-23 [20353831.001]
  • [Cites] Blood. 2006 May 1;107(9):3463-8 [16384925.001]
  • [Cites] Br J Haematol. 2010 Apr;149(1):101-10 [20067562.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jun;15(6):704-17 [19450755.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):444-53 [16344316.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 May;12(5):573-84 [16635793.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4606-13 [17873123.001]
  • [Cites] Bone Marrow Transplant. 2007 Feb;39(4):193-9 [17220905.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1357-62 [17508002.001]
  • [Cites] Am J Hematol. 2010 Apr;85(4):243-8 [20162540.001]
  • [Cites] Int J Hematol. 2007 Apr;85(3):256-63 [17483064.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):468-76 [12374451.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:384-9 [16304408.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):667-74 [16113674.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2072-7 [12357359.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):415-23 [18209726.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):660-6 [17906468.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jul;13(7):814-21 [17580259.001]
  • [Cites] Blood. 2001 Nov 15;98(10):2942-7 [11698275.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):544-51 [17141976.001]
  • (PMID = 20694843.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


32. Shen Q, Chen Z, Liu XP, Xing HY, Wang M, Wang JX: [Expression of PTEN mRNA in acute leukemia and its clinical significance]. Zhonghua Xue Ye Xue Za Zhi; 2005 Aug;26(8):493-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PTEN mRNA in acute leukemia and its clinical significance].
  • OBJECTIVE: To explore PTEN gene expression and its clinical significance in acute leukemia.
  • METHODS: The expression levels of PTEN mRNA in 5 leukemia cell lines, 87 patients with acute leukemias (AL), including 59 acute myeloid leukemia (AML), 26 acute lymphoblastic leukemia (ALL), and 2 acute hybrid leukemia, 21 AL in complete remission (AL-CR), 31 chronic myelogenous leukemia (CML) and 14 normal controls were assayed by RT-PCR.
  • [MeSH-major] Leukemia / metabolism. PTEN Phosphohydrolase / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383243.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


33. Gonen C, Celik I, Cetinkaya YS, Haznedaroglu I: Cytarabine-induced fever complicating the clinical course of leukemia. Anticancer Drugs; 2005 Jan;16(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytarabine-induced fever complicating the clinical course of leukemia.
  • The aim of this study is to assess the frequency and clinical characteristics of cytosine arabinoside-induced fever in patients with acute myeloid leukemia in remission, receiving high-dose (3 g/m2) consolidation therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Cytarabine / adverse effects. Fever / chemically induced. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Fever.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613905.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


34. Kitagawa Y, Sameshima Y, Shiozaki H, Ogawa S, Masuda A, Mori S, Teramura M, Masuda M, Kameoka S, Motoji T: Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation. Int J Hematol; 2008 May;87(4):410-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated granulocytic sarcoma of the small intestine successfully treated with chemotherapy and bone marrow transplantation.
  • Isolated primary granulocytic sarcoma is a rare disease that presents as an extramedullary tumor of myeloid lineage cells.
  • Most patients subsequently develop acute myelogenous leukemia (AML) within a short period, and their prognosis is poor.
  • Herein, we report the case of a 33-year-old woman with a primary isolated granulocytic sarcoma which originated in the small intestine.
  • After she recovered from surgery, she received intensive chemotherapy equivalent to that for AML, followed by allogeneic bone marrow transplantation from an HLA-matched, unrelated donor.
  • Four years after the transplantation, she remains in complete remission without graft-versus-host disease or any other symptoms.
  • This case illustrates the effectiveness of our therapeutic strategy for isolated granulocytic sarcoma, not only with surgical resection of the tumor and intensive chemotherapy equivalent to that for AML, but also with allogeneic bone marrow transplantation, performed while no sign of AML is observed.
  • [MeSH-major] Bone Marrow Transplantation. Intestinal Neoplasms / drug therapy. Intestine, Small / pathology. Sarcoma, Myeloid / drug therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365139.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Kilic G, Boruban MC, Bueco-Ramos C, Konoplev SN: Granulocytic sarcoma involving the uterus and right fallopian tube with negative endometrial biopsy. Eur J Gynaecol Oncol; 2007;28(4):270-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma involving the uterus and right fallopian tube with negative endometrial biopsy.
  • Granulocytic sarcoma is an extramedullary tumor associated with acute myelogenous leukemia (AML) and it is rarely seen in the female genital tract.
  • We report an unusual case of granulocytic sarcoma of the uterus and fallopian tube in an AML patient who presented with vaginal bleeding and persistent abdominal pain.
  • Biopsy did not reveal the diagnosis.
  • Pathology showed atypical myeloid cells infiltrating the muscle bundles which was consistent with granulocytic sarcoma involving the uterus and right fallopian tube.
  • Immunohistochemistry confirmed the diagnosis.
  • The patient is in complete remission for AML and being followed-up for granulocytic sarcoma.
  • Granulocytic sarcoma of the uterus and fallopian tube is very rare, and in AML patients with abnormal uterine bleeding but negative endometrial biopsy it should still be considered in the differential diagnosis.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713090.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


36. Yarranton H: Criteria for defining a complete remission in acute myeloid leukaemia. Br J Haematol; 2005 Apr;129(1):157-8; author reply 158
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Criteria for defining a complete remission in acute myeloid leukaemia.
  • [MeSH-major] Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Bone Marrow Cells / pathology. Humans. Remission Induction. Specimen Handling / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Haematol. 2005 Jan;128(2):184-91 [15638852.001]
  • (PMID = 15801968.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


37. Ishaqi MK, Afzal S, Dupuis A, Doyle J, Gassas A: Outcome of allogeneic hematopoietic stem cell transplantation for children with acute myelogenous leukemia in second complete remission: single center experience. Pediatr Transplant; 2009 Dec;13(8):999-1003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of allogeneic hematopoietic stem cell transplantation for children with acute myelogenous leukemia in second complete remission: single center experience.
  • We reviewed 26 consecutive patients with AML who were transplanted in second CR2 between 1994 and 2005.
  • Acute grade III-IV and chronic extensive GVHD occurred in eight (30%) and nine (35%) patients, respectively.
  • When entering remission, children with relapsed AML have a reasonable survival with HSCT, but relapse and TRM remain a concern.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Immunosuppressive Agents / administration & dosage. Infant. Male. Remission Induction. Retrospective Studies. Survival Rate. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome


38. Sato T, Suzuki D, Ichikawa M, Kaneda M, Nakagawa A, Kobayashi R, Ariga T: [Huge brain abscess and invasive pulmonary disease by fungal infection during chemotherapy for infantile acute myeloid leukemia]. Rinsho Ketsueki; 2007 Dec;48(12):1549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Huge brain abscess and invasive pulmonary disease by fungal infection during chemotherapy for infantile acute myeloid leukemia].
  • The authors encountered a 7-year-old girl with a huge brain abscess and invasive pulmonary lesion due to fungus, who had been treated for acute myelogenous leukemia (AML).
  • We discontinued AML treatment because of the severe fungal infection; however, she has remained in continuous remission.
  • [MeSH-major] Brain Abscess / etiology. Leukemia, Myeloid, Acute / drug therapy. Lung Diseases, Fungal / etiology. Zygomycosis / complications


39. Kim HR, Shin JH, Lee JN, Lee EY: [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia]. Korean J Lab Med; 2007 Oct;27(5):305-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of quantitation of WT1 gene expression for minimal residual disease monitoring of acute myelogenous leukemia].
  • BACKGROUND: Following induction chemotherapy for AML, a sensitive determination of minimal residual disease (MRD) in patients achieving complete remission (CR) should enable the detection of early relapse.
  • This study was designed to verify if quantitative assessment of the Wilms' tumor (WT1) gene by real time polymerase chain reaction (RQ-PCR) can be used as a marker for MRD detection during the monitoring of AML.
  • METHODS: WT1 gene expression was quantified by RQ-PCR in 31 patients with AML at diagnosis (27 patients) and during follow-up (29 patients) relative to ABL control gene.
  • Prognostic significance of WT1 gene expression was analyzed at diagnosis and at the primary CR evaluation.
  • Longitudinal WT1 gene analysis was performed in 17 AML patients.
  • RESULTS: At diagnosis, WT1 gene expression exceeded the control level in all of the patients.
  • Higher levels of WT1 gene expression were not associated with shorter event free survival or overall survival at diagnosis.
  • CONCLUSIONS: Quantitation of WT1 gene expression could be used for MRD monitoring of AML and for the early detection of relapse, especially in patients lacking specific molecular markers.
  • [MeSH-major] Genes, Wilms Tumor. Leukemia, Myelomonocytic, Acute / diagnosis. WT1 Proteins / analysis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094593.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / PRAM1 protein, human; 0 / WT1 Proteins
  •  go-up   go-down


40. Fernandez-Calotti P, Jordheim LP, Giordano M, Dumontet C, Galmarini CM: Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leuk Lymphoma; 2005 Mar;46(3):335-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute myelogenous leukemia (AML) is the most common form of acute leukemia in adults.
  • After diagnosis, patients with AML are mainly treated with standard induction chemotherapy combining cytarabine (araC) and anthracyclines.
  • The majority of them achieve complete remission (CR) (65-80%).
  • Resistance to chemotherapy therefore remains a major obstacle in the effective treatment of patients with AML.
  • [MeSH-major] Cytarabine / metabolism. Cytarabine / pharmacology. Drug Resistance, Neoplasm. Leukemia, Myeloid, Acute / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621823.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Deoxyribonucleotides; 04079A1RDZ / Cytarabine
  • [Number-of-references] 108
  •  go-up   go-down


41. Rudd E, Göransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gürgey A, Fadeel B, Nordenskjöld M, Henter JI: Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet; 2006 Apr;43(4):e14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the frequency and spectrum of mutations in the gene encoding syntaxin 11 (STX11) in familial haemophagocytic lymphohistiocytosis (FHL), a rare autosomal recessive disorder of immune dysregulation characterised by a defect in natural killer cell function.
  • Three patients experienced long periods (> or = 1 year) in remission without specific treatment, which is very uncommon in this disease.
  • Two of the six patients harbouring STX11 gene defects developed myelodysplastic syndrome (MDS) or acute myelogenous leukaemia (AML).
  • These results suggest that STX11 gene mutations may be associated with secondary malignancies (MDS/AML), and that there is segregation of specific clinical features in FHL patients with an underlying genotype.
  • [MeSH-major] Leukemia, Myeloid / genetics. Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / genetics. Mutation. Myelodysplastic Syndromes / genetics. Qa-SNARE Proteins / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged, 80 and over. Child. Child, Preschool. DNA Mutational Analysis. Female. Genotype. Humans. Infant. Male. Pedigree. Phenotype. Psychomotor Disorders / complications. Psychomotor Disorders / genetics. Remission, Spontaneous


42. de Jonge HJ, Weidenaar AC, Ter Elst A, Boezen HM, Scherpen FJ, Bouma-Ter Steege JC, Kaspers GJ, Goemans BF, Creutzig U, Zimmermann M, Kamps WA, de Bont ES: Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin Cancer Res; 2008 Feb 1;14(3):924-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.
  • PURPOSE: We hypothesized that downstream effects of endogenous vascular endothelial growth factor (VEGF)/VEGF receptor signaling on acute myelogenous leukemia (AML) cell survival resulted in increased in vitro cellular drug resistance and a longer time to kill most leukemic cells in vivo upon drug exposure.
  • EXPERIMENTAL DESIGN: In primary AML cells from pediatric patients, VEGFA and VEGFC mRNA expression and in vitro cellular resistance to nine cytotoxic drugs were studied.
  • As in vivo equivalents for in vitro drug resistance, in vivo AML blast reduction upon drug exposure, measured as blast cell reduction on day 15 in the bone marrow and as time in days from diagnosis to complete remission (CR) were used.
  • RESULTS: Increased endogenous VEGFC levels significantly correlated with increased in vitro resistance for six typical AML drugs in primary AML cells from pediatric patients.
  • Time to reach CR was studied using linear regression analysis with VEGFC, age at diagnosis, sex, treatment protocol, FAB type, cytogenetic risk profile, and WBC counts as variables.
  • CONCLUSIONS: These results suggest for the first time that higher endogenous VEGFC levels of AML cells are related to decreased in vitro and in vivo drug responsiveness.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Vascular Endothelial Growth Factor C / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245556.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


43. Hsiao PJ, Kuo SM, Chen JH, Lin HF, Chu PL, Lin SH, Ho CL: Acute myelogenous leukemia and acute leukemic appendicitis: a case report. World J Gastroenterol; 2009 Nov 28;15(44):5624-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia and acute leukemic appendicitis: a case report.
  • Acute myelogenous leukemia (AML) can involve the gastrointestinal tract but rarely involves the appendix.
  • We report a male patient who had 1 year partial remission from AML and who presented with apparent acute appendicitis as the initial manifestation of leukemia relapse.
  • Pathological findings of the appendix revealed transmural infiltrates of myeloblasts, which indicated a diagnosis of leukemia.
  • Although leukemic cell infiltration of the appendix is uncommon, patients with leukemia relapse can present with symptoms mimicking acute appendicitis.
  • [MeSH-major] Appendicitis / complications. Appendicitis / diagnosis. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Aged. Appendectomy. Disease Progression. Granulocyte Precursor Cells / cytology. Humans. Leukemic Infiltration / diagnosis. Leukemic Infiltration / pathology. Male. Recurrence. Sarcoma, Myeloid / diagnosis. Sarcoma, Myeloid / pathology. Treatment Outcome


44. Bierings M, Nachman JB, Zwaan CM: Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges. Curr Stem Cell Res Ther; 2007 Jan;2(1):53-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges.
  • The role of stem cell transplantation in the treatment of leukemia and myelodysplasia (MDS) in children has changed over the past decade.
  • In pediatric acute lymphoblastic leukemia (ALL), the overall cure-rate is high with conventional chemotherapy.
  • However, selected patients with a high-risk of relapse are often treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first remission (CR1).
  • Patients with a bone-marrow relapse who attain a second remission frequently receive HSCT.
  • In pediatric acute myeloid leukemia (AML) the role of allo-HSCT in CR1 is declining, due to better outcome with modern multi-agent chemotherapy.
  • In relapsed AML patients, allo-HSCT still seems indispensable.
  • Targeted therapy may change the role of HSCT, in particular in chronic myeloid leukemia, where the role of allografting is changing in the imatinib era.
  • [MeSH-major] Leukemia / therapy. Myelodysplastic Syndromes / therapy. Stem Cell Transplantation / trends
  • [MeSH-minor] Child. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy


45. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M: Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle; 2006 Dec;5(23):2769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells".
  • We hypothesized that studying protein expression in cells surviving in vitro chemotherapy ("survivor cells", SV), could provide more important insight into the biology of drug-resistant AML cells than analysis of the bulk population of leukemic cells.
  • Leukemia-enriched samples from 79 patients with new or relapsed AML were cultured for four days +/- cytarabine (5-10 microM).
  • The patterns of change were highly predictive of remission attainment, relapse, and survival in univariate and multivariate analysis.
  • Analysis of SV cells may be more informative than analysis of the bulk population of leukemia cells.
  • [MeSH-major] Apoptosis. Drug Resistance, Neoplasm. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy. Neoplasm Proteins / metabolism. Signal Transduction

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172852.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Neoplasm Proteins
  •  go-up   go-down


46. Hoshino T, Matsushima T, Saitoh Y, Yamane A, Takizawa M, Irisawa H, Saitoh T, Handa H, Tsukamoto N, Karasawa M, Murakami H, Nojima Y: Sacroiliitis as an initial manifestation of acute myelogenous leukemia. Int J Hematol; 2006 Dec;84(5):421-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacroiliitis as an initial manifestation of acute myelogenous leukemia.
  • We herein report a 28-year-old female patient who presented with sacroiliitis as an initial manifestation of acute myelogenous leukemia (AML).
  • Although she was initially diagnosed with myelodysplastic syndrome (MDS), blasts rapidly increased and AML developed 1 month after the diagnosis of MDS with Sacroiliitis.
  • Induction chemotherapy failed to induce a complete remission of AML, but it did effectively treat the sacroiliitis.
  • However, the sacroiliitis relapsed when the leukemia cells progressed thereafter.
  • The close relationship between the occurrence of sacroiliitis and AML suggested that autoimmune sacroiliitis was a paraneoplastic phenomenon of AML in this patient.
  • Although autoimmune disorders develop in a substantial number of MDS patients, they are rarely observed in de novo AML.
  • No previous report has described sacroiliitis as the initial manifestation of de novo AML.
  • [MeSH-major] Leukemia, Myeloid, Acute. Sacroiliac Joint. Spondylitis, Ankylosing
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Blast Crisis / diagnosis. Blast Crisis / diagnostic imaging. Blast Crisis / therapy. Bone Marrow Transplantation. Fatal Outcome. Female. Humans. Radiography. Recurrence. Transplantation, Homologous


47. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H, Pediatric Oncology Group: Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood; 2006 Feb 15;107(4):1315-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.
  • Relapse is a major obstacle in the cure of acute myeloid leukemia (AML).
  • The Pediatric Oncology Group AML Study 9421 tested 2 different strategies to improve event-free survival (EFS) and overall survival (OS).
  • Of the 282 children randomly assigned to receive standard DAT induction, 248 (87.9%) achieved remission compared to 253 (91%) of the 278 receiving high-dose DAT (P = ns).
  • Children with HLA-identical sibling donors who achieved a complete remission received an allogeneic bone marrow transplant as consolidation.
  • Of the 418 children who achieved remission and went on to consolidation with and without CsA, the DFS was 40.6% and 33.9%, respectively (P = .24).
  • In this study, intensifying induction with high-dose DAT and the addition of CsA to consolidation chemotherapy did not prolong the durations of remission or improve overall survival for children with AML.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1867-75 [10784627.001]
  • [Cites] Blood. 2000 Jul 1;96(1):365-8 [10891476.001]
  • [Cites] Blood. 2001 Jan 1;97(1):56-62 [11133742.001]
  • [Cites] Curr Oncol Rep. 2000 Nov;2(6):529-38 [11122889.001]
  • [Cites] Leukemia. 2001 Mar;15(3):348-54 [11237056.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2705-13 [11352963.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):211-33 [11355932.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):95-118 [11355926.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3605-11 [11369657.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5461-7 [11454692.001]
  • [Cites] Cell Mol Life Sci. 2001 Jun;58(7):931-59 [11497241.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] Leukemia. 2002 May;16(5):833-9 [11986944.001]
  • [Cites] Leukemia. 2002 May;16(5):920-7 [11986955.001]
  • [Cites] J Histochem Cytochem. 1977 Jul;25(7):935-41 [894009.001]
  • [Cites] Blood. 1980 Jun;55(6):960-8 [6966518.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4665-70 [1873811.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]
  • [Cites] Leukemia. 1994 Sep;8(9):1492-7 [7916390.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Apr;9(2):363-82 [7642468.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2329-42 [7545025.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2042-8 [8609715.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4809-16 [8639853.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3010-20 [8674056.001]
  • [Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]
  • [Cites] Blood. 1997 May 1;89(9):3323-9 [9129038.001]
  • [Cites] Lancet. 1998 Mar 7;351(9104):700-8 [9504514.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):315-27 [9517503.001]
  • [Cites] Br J Haematol. 1998 Apr;101(1):130-40 [9576193.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4116-24 [10361108.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1046-56 [10419897.001]
  • [CommentIn] Blood. 2006 Jun 15;107(12):4975-6; author reply 4976-7 [16754781.001]
  • (PMID = 16254147.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA90916
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / P-Glycoprotein; 094ZI81Y45 / Tamoxifen; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; LJ2P1SIK8Y / Mitolactol
  • [Other-IDs] NLM/ PMC1895393
  •  go-up   go-down


48. Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA: Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. Bone Marrow Transplant; 2008 Nov;42(10):659-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
  • Administration of alkylating agents (Alk), topoisomerase II inhibitors (Topo II) and radiotherapy (RT) can result in therapy-related myelodysplastic syndrome or acute myelogenous leukaemia (t-MDS/t-AML), the optimal treatment for which is allo-SCT.
  • A retrospective review was performed of 24 patients who underwent related- or unrelated-donor SCT for t-MDS/t-AML at our institution.
  • Eight patients remain alive and in continuous remission (median follow-up 54 months (range, 12-161)) with estimated 5-year EFS being 30% (95% confidence intervals 16-58%).
  • Corresponding actuarial risks of relapse and non-relapse mortality (NRM) are 39% (19-60%) and 30% (13-50%), respectively.
  • EFS was 40% in Alk/RT-related t-MDS/t-AML and 11% in Topo II-related t-MDS/t-AML (P=0.05), with an increased risk of relapse in the latter (56 vs 29%, respectively (P=0.05)).
  • In multivariate analysis, development of acute GVHD (P=0.009) and Topo II-related t-MDS/t-AML (P=0.018) were associated with inferior EFS.
  • Patients with acute GVHD had an increased risk of NRM (P=0.03) whereas risk of relapse was higher for patients of advanced age (P=0.046) and for patients who underwent bone marrow (vs blood) SCT (P=0.032).
  • Allo-SCT can result in long-term survival for individuals with t-MDS/t-AML although outcome in Topo II-related t-MDS/t-AML patients remains suboptimal.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Myeloablative Agonists / adverse effects. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / therapy


49. Cho BS, Kim HJ, Lee S, Eom KS, Min WS, Lee JW, Kim CC: Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia. Eur J Haematol; 2007 Aug;79(2):170-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
  • OBJECTIVES: Imatinib (Glivec, STI571) has been successfully used in patients with chronic myelogenous leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome (Ph).
  • We used imatinib interim therapy for four consecutive patients with newly diagnosed Ph+ acute myeloid leukemia (AML).
  • After the first imatinib cycle, all patients remained in sustained complete hematologic remission (CHR) with a decrease in the breakpoint cluster region of the Abelson oncogene locus transcript.
  • All patients received a second imatinib cycle following consolidation and showed sustained CHR, including two cases with complete molecular remission.
  • All cases underwent hematopoietic stem cell transplantation (HSCT) in favorable condition, and are still alive with a leukemia-free status at 6, 6, 9, and 25 months after HSCT.
  • CONCLUSIONS: As a first-line interim therapy, imatinib appears to be a useful treatment strategy to provide a bridge to HSCT in patients with Ph+ AML.
  • Further studies with a larger patient population and longer follow-up are needed for accurate assessment of the impact of imatinib on the long-term outcome of transplantation for patients with Ph+ AML.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / surgery. Piperazines / administration & dosage. Piperazines / therapeutic use. Pyrimidines / administration & dosage. Pyrimidines / therapeutic use. Stem Cell Transplantation


50. Che Y, Xu YH, Zheng GH, Guo YX: [Clinical significance of HA117 expression in children with acute leukemia]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep;40(5):873-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of HA117 expression in children with acute leukemia].
  • OBJECTIVE: To explore the role of the expression of HA117 gene in bone marrow mononuclear cells (BMMNC) with acute leukemia and multidrug resistance.
  • METHODS: HA117 gene expressions in 36 children with acute leukemia and 10 children with Idiopathic thrombocytopenic purpura (ITP) were tested using semi quantitative reverse transcriptase polymerase chain reaction (RT-PCR) technique.
  • RESULTS: The HA117 gene was expressed in 75% of children with acute leukemia.
  • There was no significant difference in HA117 gene expression between children with acute lymphoblastic leukemia (ALL, 69.57%) and children with acute myeloid leukemia (AML, 91.67%).
  • But the semi-quantitative expression of HA117/beta-actin in AML childern was significantly higher than in ALL children (q=4.5852, P<0.01).
  • The expressions of HA117 gene and HA117/beta-actin in both ALL and AML children were significantly higher than in ITP children chi2=5.05, 8.81; q=4.4612, 6.9695; P<0.05).
  • The remission patients had lower expression of HA117/beta-actin and similar expression of HA117 compared with initially diagnosed patients.
  • The remission patients had higher expression of HA117 gene and similar expression of HA117/beta-actin compared with patients with ITP.
  • The non-remission patients had higher expression of HA117/beta-actin than remission patients and ITP patients (q=3.1705, 4.4102, P<0.05), but no significant difference from initially diagnosed patients (q=0.5470, P>0.05).
  • CONCLUSION: The expression of HA117 gene is high in the BMMNC of initially diagnosed and non-remission patients with AL.
  • But the remission patients have similar semi-quantitative expression of HA117 as patients with ITP, which indicates that a quantitative testing is more important.
  • HA117 is one of the factors that may affect the clinical remission of AML.
  • The new gene HA117 may also be associated with multidrug resistance of leukemia.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Female. Humans. Infant. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Purpura, Thrombocytopenic, Idiopathic / genetics. Purpura, Thrombocytopenic, Idiopathic / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950603.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


51. Chi Y, Lindgren V, Quigley S, Gaitonde S: Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med; 2008 Nov;132(11):1835-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview.
  • Acute myelogenous leukemia (AML) with chromosomal translocation (6;9)(p23;q34) is a rare disease with poor prognosis and distinct clinical and morphologic features. t(6;9) results in a chimeric fusion gene between DEK (6p23) and CAN/NUP214 (9q34).
  • FLT3-ITD mutation is one of the most frequent mutations in AML and correlates with poor clinical outcome.
  • Prevalence of FLT3-ITD is as high as 70% among patients with t(6;9) AML, and patients with t(6;9) AML and FLT3-ITD mutations usually have higher white blood cell counts, higher bone marrow blasts, and significantly lower rates of complete remission. t(6;9) is most commonly associated with AML-FAB-M2 and is considered by some researchers to be a separate disease entity because of its distinct clinical and morphologic features and poor prognostic implication.
  • [MeSH-major] Basophils / pathology. Bone Marrow / pathology. Leukemia, Myeloid, Acute / pathology. Translocation, Genetic


52. Vey N, Giles F: Laromustine (cloretazine). Expert Opin Pharmacother; 2010 Mar;11(4):657-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IMPORTANCE OF THE FIELD: In spite of the recent progress, the prognosis of acute myelogenous leukemia (AML) remains poor, particularly in patients with relapsed disease and in the elderly.
  • AREAS COVERED IN THIS REVIEW: Preclinical and clinical studies of Laromustine (formerly cloretazine, VNP-40101M), a new sulfonylhydrazine alkylator, in AML published between 2000 and September 2009 are presented and discussed.
  • WHAT THE READER WILL GAIN: Mechanisms of action of Laromustine and preclincal data that support the rationale for its use in patients with AML are summarized.
  • In Phase II studies, it produced 32% complete responses in elderly patients with previously untreated AML.
  • In a Phase III comparative study of its combination with cytarabine in relapsed AML, increased response rate was offset by excessive toxicity.
  • TAKE HOME MESSAGE: Laromustine has significant activity in AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydrazines / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Aged. Animals. Clinical Trials, Phase II as Topic. Drug Evaluation, Preclinical. Humans. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20163276.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydrazines; 0 / Sulfonamides; 14J2G0U3NQ / laromustine
  • [Number-of-references] 84
  •  go-up   go-down


53. Slavcheva V, Lukanov T, Tzvetkov N: Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia. J BUON; 2008 Oct-Dec;13(4):589-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of extramedullary myeloid tumor in patients with continuous remission of acute myeloblastic leukemia.
  • Myeloid sarcoma is described as tumor mass consisting of myeloblasts or immature myeloid cells, involving extramedullary tissues.
  • It can be initial manifestation of myeloproliferative disorders or relapse of previously treated acute myeloblastic leukemia (AML).
  • We present two patients, one with AML-M2 and the other with acute promyelocytic leukemia (APL)-M3.
  • After remission induced by conventional chemotherapy, which continued for 3 and 10 years respectively, a myeloid sarcoma was diagnosed.
  • Two years after the diagnosis of myeloid sarcoma the patient died of haemorrhagic stroke.
  • The patient with AML-M2 continued treatment with polychemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Promyelocytic, Acute / pathology. Sarcoma, Myeloid / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145688.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


54. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M: Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res; 2009 May 15;15(10):3325-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.
  • However, mechanisms of suppression and clinical significance of Treg, especially in patients with acute myelogenous leukemia (AML), has not been well defined.
  • EXPERIMENTAL DESIGN: We prospectively evaluated the phenotype, function, and mechanisms of suppression used by Treg in newly diagnosed untreated AML patients.
  • RESULTS: The percentage of circulating Treg was higher (P < 0.0001) and their phenotype was distinct in AML patients relative to normal controls.
  • Suppression mediated by Treg coincubated with proliferating autologous responder cells was also higher (P < 0.001) in AML than that mediated by control Treg.
  • Unexpectedly, patients who achieved complete remission still had elevated frequency of Treg, which mediated high levels of suppressor activity.
  • CONCLUSIONS: Treg accumulating in the peripheral circulation of AML patients mediate vigorous suppression via contact-dependent and contact-independent mechanisms.
  • Patients with lower Treg frequency at diagnosis have a better response to induction chemotherapy.
  • During the post-induction period, the Treg frequency and suppressive activity remain elevated in complete remission, suggesting that Treg are resistant to conventional chemotherapy.
  • [MeSH-major] Leukemia, Myeloid / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Acute Disease. Adenosine Triphosphate / metabolism. Antigens, CD4 / immunology. Cytokines / metabolism. Flow Cytometry. Humans. Immunophenotyping. Interleukin-2 Receptor alpha Subunit / immunology. Prognosis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4766-72 [11406550.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):135-42 [11812990.001]
  • [Cites] J Exp Med. 2002 Nov 18;196(10):1335-46 [12438424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):345-52 [15785760.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2186-8 [15928036.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):3-15 [16153857.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):383-93 [16622476.001]
  • [Cites] Blood. 2006 Aug 1;108(3):804-11 [16861339.001]
  • [Cites] Cell. 2006 Jul 28;126(2):253-6 [16873058.001]
  • [Cites] Cell. 2006 Jul 28;126(2):375-87 [16873067.001]
  • [Cites] J Immunol. 2007 Jan 1;178(1):320-9 [17182569.001]
  • [Cites] Blood. 2007 Jan 1;109(1):323-30 [16940427.001]
  • [Cites] Eur J Immunol. 2007 Jan;37(1):21-3 [17183612.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1257-65 [17502665.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1225-32 [17449799.001]
  • [Cites] Cancer Immunol Immunother. 2007 Nov;56(11):1743-53 [17487490.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8344-50 [17804750.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2473-83 [17691114.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6301-11 [17975141.001]
  • [Cites] Surg Oncol Clin N Am. 2007 Oct;16(4):755-74, viii [18022543.001]
  • [Cites] Leuk Res. 2008 Apr;32(4):651-8 [17920118.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1557-69 [18725574.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • (PMID = 19417016.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA109688; United States / NCI NIH HHS / CA / P01 CA109688
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Cytokines; 0 / Interleukin-2 Receptor alpha Subunit; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ NIHMS482697; NLM/ PMC3700356
  •  go-up   go-down


55. Kim SC, Natarajan-Ame S, Lioure B, Chenard MP, Duclos B, Herbrecht R, Bergerat JP: Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up. J Oncol; 2010;2010:812424
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up.
  • Background. Localized granulocytic sarcoma of the uterine cervix in the absence of acute myelogenous leukemia (AML) at presentation is very rare, its diagnosis is often delayed, and its prognosis almost always ominous evolving into refractory AML. Case.
  • Further evaluation confirmed the presence of a granulocytic sarcoma but failed to reveal systemic involvement.
  • Results. AML type chemotherapy followed by radiotherapy of the uterus led to a durable complete remission.
  • She remains in complete remission six years after diagnosis.
  • Conclusion. Granulocytic sarcoma of the cervix is a rare entity for which early intensive AML type therapy is effective.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med J. 2006 Oct;36(10):669-71 [16958646.001]
  • [Cites] Gynecol Oncol. 2005 Sep;98(3):493-7 [16019058.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1156-65 [9331287.001]
  • [Cites] Nouv Rev Fr Hematol. 1995;37(5):273-6 [8700651.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):553-7 [15228434.001]
  • [Cites] Br J Radiol. 1989 Nov;62(743):995-8 [2510900.001]
  • [Cites] J Clin Pathol. 1989 May;42(5):483-8 [2732341.001]
  • [Cites] Cancer. 1984 Apr 15;53(8):1764-6 [6582998.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Clin Lab Med. 1990 Dec;10(4):889-901 [2272180.001]
  • (PMID = 20454648.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2862322
  •  go-up   go-down


56. Wang LH, Wang M, Zhou CL, Chen S, Zhang XW, Xing HY, Wang JX: [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2005 Jun;26(6):335-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
  • OBJECTIVE: To evaluate the prevalence of a novel FLT3 activating mutation in tyrosine kinase domain (TDK) in acute leukemia patients and its clinical implication.
  • METHODS: Genomic DNA from bone marrow mononuclear cells of 143 cases of acute myeloid leukemia (AML), 25 acute lymphocytic leukemia (ALL), 2 acute hybrid leukemia (AHL), 17 myelodysplastic syndromes (MDS) and 7 chronic myelogenous leukemia in blast crisis (CML-BC) was screened by polymerase chain reaction (PCR) and gel electrophoresis for FLT3-TKD point mutations.
  • RESULTS: Among AML patients, FLT3-TKD point mutation (FLT3-TKD(+)) rate was 6.3% (9/143), an incidence significantly lower than that of internal tandem duplication (ITD) mutation (37/143, 25.9%, P < 0.01).
  • In contrast to FLT3-ITD mutation, TKD mutations were not associated with leukocytosis or low complete remission rate.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. fms-Like Tyrosine Kinase 3 / genetics


57. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN: Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer; 2010 Sep 1;116(17):4063-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
  • BACKGROUND: : Acute kidney injury (AKIis a common complication in the treatment of patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS), but, to the authors' knowledge, its clinical relevance has not been detailed to date.
  • The objective of the current study was to identify the incidence, predictors, and outcome for AKI in patients with AML and HR-MDS.
  • METHODS: : Data were analyzed from 537 patients with AML or HR-MDS undergoing induction chemotherapy from 1999 to 2007.
  • Significant independent risk factors for AKI included the following: age >/=55 years (odds ratio [OR], 1.8), mechanical ventilation (OR, 16), use of vancomycin (OR, 2.3), diuretics (OR, 3.0), amphotericin B lipid formulation (OR, 2.7), vasopressors (OR, 4.9), leukopenia (OR, 1.9), hypoalbuminemia (OR, 1.4), and use of non-fludarabine-based chemotherapy (OR, 2.7).
  • The 8-week mortality rates were 3.8%, 13.6%, 19.6%, and 61.7% for the non-RIFLE, Risk, Injury, and Failure categories, respectively.
  • Survival of patients who achieved complete remission was favorable, regardless of degree of AKI.
  • CONCLUSIONS: : The RIFLE classification for AKI appears to have prognostic utility in predicting mortality in patients with AML or HR-MDS.
  • [MeSH-major] Acute Kidney Injury / epidemiology. Leukemia, Myeloid, Acute / complications. Myelodysplastic Syndromes / complications


58. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood; 2006 Feb 15;107(4):1325-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Donor lymphocyte infusions (DLIs) induce potent graft versus tumor (GVT) effects for relapsed chronic myelogenous leukemia (CML) after allogeneic stem cell transplantation (SCT) but are disappointing for other diseases.
  • Seven patients developed acute graft versus host disease (GVHD) (5 grade I-II, 2 grade III), and 4 developed chronic GVHD.
  • Eight patients achieved complete remission, including 4 of 7 with acute lymphocytic leukemia (ALL), 2 of 4 with acute myelogenous leukemia (AML), 1 with chronic lymphocytic leukemia (CLL), and 1 of 2 with non-Hodgkin lymphoma (NHL).
  • Four complete responders relapsed while 4 remain alive in remission a median 23 months after aDLI.
  • [MeSH-major] Antigens, CD28 / blood. Antigens, CD8 / blood. Leukemia / therapy. Lymphocyte Transfusion / adverse effects. Lymphoma / therapy. Stem Cell Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269610.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD28; 0 / Antigens, CD8
  •  go-up   go-down


59. Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S: Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. Biol Blood Marrow Transplant; 2008 Jun;14(6):651-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
  • We retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with de novo acute myelogenous leukemia (AML).
  • At HSCT, 35 patients were in the first or second complete remission (CR1/2), and 15 patients were not in remission (n = 14) or in the third CR (n = 1).
  • The 5-year estimated overall survival (OS) and disease-free survival (DFS) rates were 85.5% (95% confidence interval [CI], 73.7%-97.3%) and 82.1% (95% CI, 69.0%-95.2%) in patients with AML in the first or second CR, 46.7% (95% CI, 21.4%-72.0%), and 40.0% (95% CI, 15.3%-64.7%) in patients with AML in other stages.
  • These results suggest that G-CSF-combined high-dose cytarabine could be a promising component of the conditioning regimen for allogeneic HSCT for AML, providing a high DFS and low TRM.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / surgery. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation / adverse effects. Bone Marrow Transplantation / mortality. Cytarabine / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Leukemia, Myelomonocytic, Acute / mortality. Leukemia, Myelomonocytic, Acute / surgery. Male. Middle Aged. Recombinant Proteins / administration & dosage. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489990.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6WS4C399GB / lenograstim
  •  go-up   go-down


60. Hanbali A, Wollner I, Neme K, Ulreich C: Fatal hypersensitivity reaction to gemtuzumab ozogamicin associated with platelet transfusion. Am J Health Syst Pharm; 2007 Jul 1;64(13):1401-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was diagnosed with acute myelogenous leukemia (AML).
  • He went into partial remission and received two cycles of cytarabine and idarubicin followed by one cycle of high-dose cytarabine.
  • CONCLUSION: A patient with AML developed severe respiratory distress and died after receiving gemtuzumab and 6 units of platelets on the same day.
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Fatal Outcome. Humans. Leukemia, Myeloid, Acute / drug therapy. Male

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592005.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


61. Headley CM, Ioffreda MD, Zaenglein AL: Neutrophilic eccrine hidradenitis: a case report of an unusual annular presentation. Cutis; 2005 Feb;75(2):93-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neutrophilic eccrine hidradenitis (NEH) is an acute, self-limited, inflammatory neutrophilic dermatosis.
  • It is most commonly described in patients with acute myelogenous leukemia (AML) following chemotherapy.
  • [MeSH-major] Hidradenitis / diagnosis. Immunocompromised Host. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / immunology. Remission Induction
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Recurrence. Remission, Spontaneous. Risk Assessment

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773529.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Trof RJ, Beishuizen A, Wondergem MJ, Strack van Schijndel RJ: Spontaneous remission of acute myeloid leukaemia after recovery from sepsis. Neth J Med; 2007 Jul-Aug;65(7):259-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute myeloid leukaemia after recovery from sepsis.
  • Spontaneous remission of acute myeloid leukaemia (AML) is extremely rare and usually of short duration.
  • We report two patients with documented AML who developed spontaneous remission of their leukaemia shortly after an episode of severe sepsis and respiratory failure requiring mechanical ventilation.
  • The underlying mechanisms of spontaneous remission remain unclear but an association with preceding blood transfusions and severe systemic infections has been reported.
  • Better insights into the mechanisms of spontaneous remission of AML after recovery from sepsis could help in developing new therapies for AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Sepsis / complications
  • [MeSH-minor] Adult. Anti-Bacterial Agents / administration & dosage. Antineoplastic Agents / administration & dosage. Humans. Intensive Care Units. Iraq / ethnology. Male. Netherlands. Pulmonary Ventilation. Remission, Spontaneous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656812.001).
  • [ISSN] 0300-2977
  • [Journal-full-title] The Netherlands journal of medicine
  • [ISO-abbreviation] Neth J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


63. Al-Shehri A, Al-Seraihy A, Owaidah TM, Belgaumi AF: Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther; 2010;3(1):42-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia.
  • Patients with chronic myeloid leukemia (CML) infrequently present in blast crisis (BC).
  • While most BC are of myeloid origin, megakaryocytic BC is rare, especially at the time of CML diagnosis.
  • We describe the first pediatric patient presenting with megakaryocytic leukemia and having BCR-ABL1 translocation as the single chromosomal abnormality.
  • Clinical features were more suggestive of CML in megakaryocytic blast crisis than Philadelphia chromosome positive de novo AML.
  • The patient was treated with AML-directed chemotherapy and imatinib mesylate followed by umbilical cord blood stem cell transplantation.
  • [MeSH-major] Blast Crisis / pathology. Leukemia, Megakaryoblastic, Acute / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Megakaryocytes / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Child. Cord Blood Stem Cell Transplantation. Diagnosis, Differential. Female. Humans. Imatinib Mesylate. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Remission Induction. Treatment Outcome


64. Kinoshita T, Yokokawa M, Yashiro N: Multicentric granulocytic sarcoma of the breast: mammographic, sonographic, and MR findings. Clin Imaging; 2006 Jul-Aug;30(4):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric granulocytic sarcoma of the breast: mammographic, sonographic, and MR findings.
  • A rare case of granulocytic sarcoma (GS) of the bilateral breasts after complete remission of acute myelogenous leukemia is reported.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Sarcoma, Myeloid / diagnosis. Ultrasonography
  • [MeSH-minor] Female. Humans. Middle Aged. Rare Diseases / diagnosis


65. Giles F, O'Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H: Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer; 2005 Aug 1;104(3):547-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with acute myelogenous leukemia after second salvage therapy.
  • BACKGROUND: Although the prognosis is poor for patients with acute myelogenous leukemia (AML) who have disease recurrence after frontline therapy, this is a general reflection of first salvage therapies.
  • The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival.
  • METHODS: The records of 594 patients with AML undergoing second salvage therapy from 1980 until 2004 were reviewed.
  • Salvage therapy included allogeneic stem cell transplantation (SCT) in 74 patients, standard-dose cytosine arabinoside (ara-C) combinations in 30 patients, high-dose ara-C combinations in 171 patients, non-ara-C combinations in 73 patients, and Phase I-II single agents in 246 patients.
  • A multivariate analysis of prognostic factors for CR identified the following 6 independent adverse factors: first CR duration < 6 months; second CR duration < 6 months; salvage therapy not including allogeneic SCT; non-inversion 16 AML; platelet counts < 50 x 10(9)/L, and leukocytosis > 50 x 10(9)/L.
  • CONCLUSIONS: The current analysis established the outcome and prognostic factors associated with second salvage therapy in AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / therapy. Salvage Therapy. Stem Cell Transplantation. Transplantation, Homologous
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Cytarabine / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Survival Rate. Treatment Outcome


66. Bogason A, Bhuiyan H, Masquelier M, Paul C, Gruber A, Vitols S: Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response. Eur J Clin Pharmacol; 2009 Dec;65(12):1179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.
  • AIMS: To study anthracycline-induced apoptosis in leukemic cells isolated from patients with acute myelogenous leukemia (AML) in vitro and to compare intracellular anthracycline concentrations causing apoptosis in vitro with those obtained in vivo during anthracycline treatment.
  • METHODS: Mononuclear blood cells from AML patients were isolated before (n = 20) and after anthracycline infusion (n = 24).
  • The intracellular concentrations of DNR in vivo (n = 24) were more than tenfold lower than the concentrations needed to induce effective apoptosis in vitro, although a significant relation between in vivo concentrations and clinical remission was found.
  • We also found a significant relation between apoptosis induction in leukemic cells by IDA in vitro and clinical remission.
  • [MeSH-major] Anthracyclines / pharmacokinetics. Anthracyclines / pharmacology. Apoptosis / drug effects. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1989;13(2):191-6 [2927175.001]
  • [Cites] Adv Exp Med Biol. 1999;457:437-44 [10500820.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;13(3):230-4 [6488444.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):324-9 [7914424.001]
  • [Cites] Leukemia. 2001 Jun;15(6):898-902 [11417474.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 1968;97:77-89 [4179068.001]
  • [Cites] Pharmacol Ther. 1993 Nov;60(2):185-214 [8022857.001]
  • [Cites] Mol Pharmacol. 1994 Nov;46(5):901-8 [7969078.001]
  • [Cites] Ther Drug Monit. 1989;11(2):140-8 [2718219.001]
  • [Cites] Leuk Res. 1999 Jun;23(6):539-48 [10374847.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):266-72 [1380280.001]
  • [Cites] Oncology (Williston Park). 1991 Sep;5(9):93-103; disc. 104, 111-4, 117-8 [1835882.001]
  • [Cites] Acta Biochim Pol. 2002;49(1):99-107 [12136962.001]
  • [Cites] Leukemia. 1988 Aug;2(8):511-7 [3166077.001]
  • [Cites] Klin Padiatr. 2007 May-Jun;219(3):134-8 [17525906.001]
  • [Cites] Bull Exp Biol Med. 2004 Aug;138(2):114-8 [15662449.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;20(4):311-5 [3690804.001]
  • [Cites] Curr Drug Metab. 2001 Dec;2(4):355-66 [11766987.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):802-12 [3163363.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1266-75 [10914552.001]
  • [Cites] Eur J Haematol. 2001 Mar;66(3):160-7 [11350484.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Acta Oncol. 2001;40(2-3):231-52 [11441935.001]
  • [Cites] Biochem Pharmacol. 2004 Mar 15;67(6):1047-56 [15006541.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):206-10 [2765367.001]
  • [Cites] Br J Haematol. 1992 Jul;81(3):455-6 [1390226.001]
  • [Cites] Eur J Haematol. 1992 May;48(5):254-8 [1353726.001]
  • [Cites] Cancer Lett. 2002 Apr 25;178(2):141-9 [11867198.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;12(2):125-30 [6697426.001]
  • [Cites] Leukemia. 1996 Jun;10(6):937-42 [8667648.001]
  • [Cites] Cancer Lett. 1984 Oct;24(3):305-9 [6594191.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2147-53 [7536492.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 26;280(3):951-9 [11162617.001]
  • (PMID = 19820921.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anthracyclines; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


67. Claxton DF, Ehmann C, Rybka W: Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol; 2005 Jul;130(2):256-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
  • Non-myeloablative conditioning has extended the use of allogeneic haematopoietic transplant to many previously ineligible patients.
  • A total of 23 patients with acute myelogenous leukaemia (AML) were treated, with a median age of 59 years (range: 28-72) at transplant.
  • Only seven patients in total were in complete remission prior to transplantation.
  • Four of 12 survivors relapsed at 83, 88, 243 and 508 d and three were in remission after chemotherapy and donor lymphocyte infusion.
  • Although follow up is short, this data suggests that non-myeloablative haematopoietic cell transplantation with sirolimus (rapamycin)-based immunosuppression may provide disease control over several years in some patients with advanced and poor prognosis AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Immunosuppressive Agents / administration & dosage. Leukemia, Myeloid, Acute / therapy. Sirolimus / administration & dosage

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029454.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


68. Ito K, Tominaga K, Suzuki T, Jinnai I, Bessho M: Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia. Int J Hematol; 2005 Apr;81(3):242-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
  • Philadelphia (Ph) chromosome-positive acute myelogenous leukemia (AML) is a rare disease that is resistant to conventional antitumor chemotherapy and has a poor prognosis.
  • We describe a case of Ph chromosome-positive AML in which imatinib mesylate was used and a favorable outcome was obtained.A 64-year-old man was found to have Ph chromosome-positive, minor BCR-ABL-positive AML.
  • Remission could not be induced by remission induction therapy with antitumor agents.
  • Our results suggested that imatinib mesylate was very useful for treating Ph chromosome-positive AML.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / administration & dosage. Pyrimidines / administration & dosage
  • [MeSH-minor] Benzamides. Humans. Imatinib Mesylate. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / physiopathology. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814335.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


69. Paugam A: [The latest data on posaconazole]. Med Mal Infect; 2007 Feb;37(2):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Posaconazole was recently indicated for prophylaxis of invasive fungal infections in the following patients: patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for versus host disease.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267154.001).
  • [ISSN] 0399-077X
  • [Journal-full-title] Médecine et maladies infectieuses
  • [ISO-abbreviation] Med Mal Infect
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Triazoles; 0 / Trypanocidal Agents; 6TK1G07BHZ / posaconazole
  • [Number-of-references] 65
  •  go-up   go-down


70. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, Panetta P, Consalvo MI, Mazzone C, Neri B, Ottaviani L, Fraboni D, Tamburini A, Lo-Coco F, Amadori S, Venditti A: The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia; 2006 Oct;20(10):1783-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
  • We assessed by multiparametric flow cytometry the levels of minimal residual disease (MRD) in 100 adult patients with acute myelogenous leukemia (AML) achieving complete remission after intensive chemotherapy.
  • (1) the threshold of 3.5 x 10(-4) is valid in discriminating risk categories in adult AML and (2) post-Cons MRD assessment is critical to predict disease outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / pathology. Neoplasm, Residual / mortality. Neoplasm, Residual / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Flow Cytometry. Humans. Immunophenotyping. Kinetics. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838027.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


71. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima M: Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant; 2009 Sep;15(9):1094-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied 141 patients diagnosed with acute myelogenous leukemia (AML) (n = 131) or high-risk myelodysplastic syndrome (MDS) (n = 10) who underwent allogeneic transplantation with fludarabine (Flu)/melphalan (Mel)-based regimens and hypothesized that moderate to mild renal function impairment increases NRM in this setting.
  • Disease status at transplantation was complete remission (n = 56, 40%) or active disease (n = 85, 60%).
  • [MeSH-major] Acute Kidney Injury / physiopathology. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Melphalan / administration & dosage. Myelodysplastic Syndromes / therapy. Transplantation Conditioning / methods. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Glomerular Filtration Rate. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Young Adult


72. Marisavljevic D, Markovic O, Zivkovic R: An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase. Med Oncol; 2009 Dec;26(4):476-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of smoldering AML with prolonged indolent clinical course and spontaneous remission in the terminal phase.
  • An unusual case of acute myeloblastic leukemia (AML) with indolent clinical course and spontaneous remission in the terminal phase is described.
  • A 63-year-old male has been diagnosed to suffer from AML, subtype M2.
  • Clinical course was slowly progressive ("smoldering" AML).
  • Five years from diagnosis patient exhibited spontaneous remission of the disease, accompanied with disappearance of del(6q) clone.
  • Additional curiosity in this case is the fact that patient's older brother died of acute lymphoblastic leukemia at the age of 71 years.
  • Possible mechanisms of spontaneous remission of AML and genetic predisposition for human leukemia are discussed with a review of the literature.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Regression, Spontaneous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):375-82 [9684934.001]
  • [Cites] Eur J Haematol. 2002 Jun;68(6):376-81 [12225396.001]
  • [Cites] Br J Haematol. 1994 Jan;86(1):210-2 [8011534.001]
  • [Cites] Ann Hematol. 2001 Jul;80(7):423-5 [11529469.001]
  • [Cites] Ann Hematol. 1996 Oct;73(4):189-93 [8890708.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Feb;58(2):181-5 [1551086.001]
  • [Cites] Leuk Res. 2001 Jan;25(1):33-38 [11137558.001]
  • [Cites] Am J Hum Genet. 1996 Nov;59(5):990-8 [8900225.001]
  • [Cites] Cancer. 1997 Dec 1;80(11 Suppl):2205-9 [9395035.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):557-60 [16396781.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):418-23 [15813916.001]
  • [Cites] Ann Hematol. 2004 Mar;83(3):189-94 [15064869.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2055-61 [12357357.001]
  • [Cites] Int J Hematol. 2001 Aug;74(2):173-7 [11594518.001]
  • [Cites] J Natl Cancer Inst. 1969 Mar;42(3):517-24 [4180615.001]
  • [Cites] Eur J Haematol. 2004 Jul;73(1):62-6 [15182340.001]
  • [Cites] Int J Lab Hematol. 2007 Oct;29(5):386-9 [17824921.001]
  • [Cites] Eur J Haematol. 2004 Sep;73(3):219-22 [15287921.001]
  • [Cites] Leuk Lymphoma. 1999 Aug;34(5-6):561-7 [10492080.001]
  • (PMID = 19130323.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Sakhinia E, Faranghpour M, Liu Yin JA, Brady G, Hoyland JA, Byers RJ: Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol; 2005 Jul;130(2):233-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow.
  • Cancer subtype diagnosis using microarray signatures has the potential to transform pathological diagnosis but the routine measurement of genes signatures remains difficult.
  • Reverse transcription polymerase chain reaction (RT-PCR) measurement of Indicator genes for acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) was used to determine gene signatures.
  • The expression profile of the 17 top-ranked genes distinguishing AML and ALL were measured by RT-PCR in five ALL, 26 AML, 12 AML remission, four chronic myeloid leukaemia (CML) and nine morphologically normal BM samples.
  • All but two of the genes measured showed similar expression in AML and ALL to that reported previously.
  • Specifically, c-MYB (P </= 0.04) was significantly increased in ALL in the total fraction, whilst HOXA9 (P </= 0.19) and cystatin c (P </= 0.01) were increased in AML in the CD34(+) and CD34(-) fractions, respectively. c-MYB, hSNF2, RBAP48, HKRT-1, LYN, CD33, Adipsin and HOXA9 were increased in AML compared with remission AML, indicating an ability to determine disease activity.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adult. Antigens, CD34 / analysis. Bone Marrow Cells / metabolism. Cluster Analysis. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029452.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / DNA, Neoplasm
  •  go-up   go-down


74. Usuki K, Urabe A, Ikeda Y, Ohashi Y, Mizoguchi H, Takaku F, Japan IL-11 Study Group: A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia. Int J Hematol; 2007 Jan;85(1):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.
  • To investigate the efficacy of using recombinant human interleukin 11 (rhIL-11) to reduce the need for platelet transfusions, we performed a randomized, double-blind phase II/III study with 110 acute myelogenous leukemia (AML) patients in the first complete remission.
  • These results show that rhIL-11 does not reduce the platelet transfusion requirement in AML patients, but the retrospective analysis confirms the previous finding that rhIL-11 reduces infection in patients undergoing chemotherapy.
  • [MeSH-major] Interleukin-11 / administration & dosage. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 May 15;93(10):3467-72 [10233899.001]
  • [Cites] Lancet. 1991 Nov 16;338(8777):1223-6 [1682642.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):319-26 [8547068.001]
  • [Cites] Transfusion. 1998 Jul;38(7):625-36 [9683100.001]
  • [Cites] Br J Haematol. 2005 Jan;128(1):49-58 [15606549.001]
  • [Cites] J Clin Oncol. 2001 Nov 1;19(21):4165-72 [11689585.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Blood. 1988 Sep;72(3):970-7 [3416080.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1018-27 [10400417.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):765-9 [1825140.001]
  • [Cites] Ann Hematol. 2003 Nov;82(11):677-83 [14530872.001]
  • [Cites] N Engl J Med. 1997 Dec 25;337(26):1870-5 [9407153.001]
  • [Cites] Blood. 1996 May 1;87(9):3607-14 [8611684.001]
  • [Cites] Blood. 1998 May 15;91(10):3607-15 [9572995.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):103-12 [11841402.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3368-77 [9363868.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1499-506 [8123841.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4710-8 [9389686.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1519-38 [11230498.001]
  • [Cites] N Engl J Med. 1997 Feb 6;336(6):404-9 [9010146.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):265-9 [3567081.001]
  • [Cites] Blood. 1993 Jan 1;81(1):27-34 [8417798.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3694-701 [10572081.001]
  • [Cites] Eur J Haematol. 1993 Mar;50(3):160-7 [8472811.001]
  • [Cites] Blood. 1992 Jan 15;79(2):327-31 [1370382.001]
  • [Cites] Blood. 1993 Feb 15;81(4):901-8 [8427998.001]
  • [Cites] Leukemia. 1996 Jun;10(6):964-9 [8667653.001]
  • [Cites] Biol Blood Marrow Transplant. 1998;4(3):134-41 [9923411.001]
  • [Cites] Blood. 2002 Jun 15;99(12 ):4343-9 [12036860.001]
  • [Cites] Ann Intern Med. 1997 May 1;126(9):673-81 [9139552.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2954-65 [9256140.001]
  • [Cites] Oral Oncol. 2000 Jul;36(4):373-81 [10899677.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2530-5 [10753831.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3897-908 [9166826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7512-6 [2145578.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3):253-60 [9685171.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):275-80 [12559860.001]
  • [Cites] N Engl J Med. 1990 Jun 7;322(23):1646-51 [2342524.001]
  • [Cites] Blood. 1993 Mar 15;81(6):1586-92 [8453105.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1710-7 [8634416.001]
  • [Cites] Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S53-5 [15250022.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1448-51 [1832057.001]
  • [Cites] Blood. 1996 May 1;87(9):3615-24 [8611685.001]
  • [Cites] Blood. 1994 Jan 1;83(1):33-7 [8274749.001]
  • (PMID = 17261503.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukin-11; 0 / Placebos; 0 / Recombinant Proteins
  •  go-up   go-down


75. Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A, Van Lint MT, Gobbi M, Miglino M, Clavio M, Risso M, Frassoni F, Bacigalupo A: Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant; 2007 Aug;40(4):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant.
  • We assessed the outcome of 170 patients with AML in first complete remission, aged 1-47 years (median 29), who had undergone an allogeneic BMT before or after 1990 (n=80 and n=90, respectively); all patients were prepared with cyclophosphamide and TBI; the median follow-up for surviving patients was 13 years.
  • Patients transplanted after 1990 were older, had a shorter interval diagnosis-BMT, had less FAB-M3 cases, received a higher dose of TBI, a higher marrow cell dose and combined (cyclosporine+methotrexate) GVHD prophylaxis.
  • In conclusion, the overall survival of first remission AML undergoing an allogeneic BMT has almost doubled in the past two decades, despite older age and fewer M3 cases.
  • [MeSH-major] Bone Marrow Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cohort Studies. Female. Graft vs Host Disease / prevention & control. Graft vs Host Disease / therapy. Humans. Infant. Italy / epidemiology. Male. Neoplasm Recurrence, Local / therapy. Remission Induction / methods. Risk. Survival Analysis. Transplantation, Homologous


76. Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, Lee KB: Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma; 2005 Jun;46(6):885-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
  • The present study evaluated the serum levels of known angiogenic factors and analysed their prognostic significance in patients with acute or chronic leukemia.
  • Enzyme-linked immunosorbent assays (ELISAs) were performed to quantify the basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), tumor necrosis factor-alpha (TNF-alpha), angiogenin, and matrix metalloproteinase-9 (MMP-9) in stored samples obtained before treatment from patients with acute myeloid leukemia (AML; 30 patients), acute lymphoblastic leukemia (ALL; 10 patients), and chronic myelogenous leukemia (CML; 14 patients).
  • The HGF levels were also higher in patients with AML than in healthy individuals, plus there was a significant correlation between the HGF level and the white blood cell count, monocyte count, and serum level of lactate dehydrogenase (LDH) in patients with AML.
  • In a univariate analysis, age and HGF level were both found to be significant parameters predictive for an achievement of complete remission (CR) in patients with AML.
  • The leukemia-free survival (LFS) rate for AML patients with a lower HGF concentration was better than that for AML patients with a higher HGF concentration (1 year LFS rates=75.0% vs. 37.5%, P=0.065).
  • The HGF concentration was an independent prognostic factor for an achievement of CR, plus higher HGF concentrations were associated with a lower survival in patients with AML.
  • [MeSH-major] Hepatocyte Growth Factor / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neovascularization, Pathologic. Prognosis. Remission Induction


77. Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR: Leukemia regression by vascular disruption and antiangiogenic therapy. Blood; 2010 Sep 2;116(9):1539-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia regression by vascular disruption and antiangiogenic therapy.
  • Acute myelogenous leukemias (AMLs) and endothelial cells depend on each other for survival and proliferation.
  • Monotherapy antivascular strategies such as targeting vascular endothelial growth factor (VEGF) has limited efficacy in treating AML.
  • Thus, in search of a multitarget antivascular treatment strategy for AML, we tested a novel vascular disrupting agent, OXi4503, alone and in combination with the anti-VEGF antibody, bevacizumab.
  • Using xenotransplant animal models, OXi4503 treatment of human AML chloromas led to vascular disruption in leukemia cores that displayed increased leukemia cell apoptosis.
  • However, viable rims of leukemia cells remained and were richly vascular with increased VEGF-A expression.
  • To target this peripheral reactive angiogenesis, bevacizumab was combined with OXi4503 and abrogated viable vascular rims, thereby leading to enhanced leukemia regression.
  • In a systemic model of primary human AML, OXi4503 regressed leukemia engraftment alone and in combination with bevacizumab.
  • Differences in blood vessel density alone could not account for the observed regression, suggesting that OXi4503 also exhibited direct cytotoxic effects on leukemia cells.
  • Together, these data show that OXi4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevacizumab mitigates reactive angiogenesis.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 1;95(1):309-13 [10607717.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1318-27 [10604728.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1870-5 [9058706.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):815-21 [9060819.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1829-34 [9157969.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1A):189-95 [10226542.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1109-17 [15718307.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1154-63 [15870183.001]
  • [Cites] Hematology. 2005 Dec;10(6):483-94 [16321813.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4090-4 [16818709.001]
  • [Cites] Haematologica. 2006 Sep;91(9):1203-11 [16956819.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2313-21 [16921487.001]
  • [Cites] Bioorg Med Chem. 2007 Jan 15;15(2):605-15 [17070061.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1310-2 [17330095.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1862-71 [17446561.001]
  • [Cites] Chem Res Toxicol. 2007 Dec;20(12):1885-94 [17941699.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1951-61 [18024794.001]
  • [Cites] Leukemia. 2008 Feb;22(2):287-93 [17943167.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4B):2027-31 [18751370.001]
  • [Cites] Cell Tissue Res. 2009 Jan;335(1):241-8 [18752004.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):53-68 [19016730.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Feb;18(2):189-97 [19236265.001]
  • [Cites] Stem Cells Dev. 2009 Oct;18(8):1235-42 [19105599.001]
  • [Cites] Expert Opin Investig Drugs. 2010 Feb;19(2):169-83 [20050812.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2121-9 [11264180.001]
  • [Cites] Anticancer Res. 2001 Jan-Feb;21(1A):93-102 [11299795.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2637-44 [10753845.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1369-76 [11516097.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62 [11553814.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2060-9 [11877280.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2179-84 [11877295.001]
  • [Cites] Acta Oncol. 2002;41(1):98-105 [11990526.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1302-10 [12094254.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1453-8 [12168822.001]
  • [Cites] Nat Med. 2003 Jun;9(6):677-84 [12778166.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1433-40 [12820406.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2763-7 [12843001.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3577-85 [15173063.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2491-9 [15197790.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1369-73 [15359635.001]
  • [Cites] Leuk Lymphoma. 2004 Jun;45(6):1185-90 [15359999.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3717-21 [10572084.001]
  • [CommentIn] Blood. 2010 Sep 2;116(9):1389-90 [20813902.001]
  • (PMID = 20472832.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK067359; United States / NCI NIH HHS / CA / CA084408; United States / NCI NIH HHS / CA / CA089655; United States / NCI NIH HHS / CA / R01 CA089655; United States / NHLBI NIH HHS / HL / R01 HL070738; United States / NCI NIH HHS / CA / R01 CA084408
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Diphosphates; 0 / Il2rg protein, mouse; 0 / Interleukin Receptor Common gamma Subunit; 0 / Oxi 4503; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Stilbenes; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2938842
  •  go-up   go-down


78. Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, Pandolfi PP, Nimer SD: Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res; 2008 Feb 1;14(3):826-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
  • PURPOSE: Epigenetic modulation of gene expression plays an important role in cancer, including leukemia.
  • The purpose of this study was to evaluate the toxicity, pharmacokinetic profile, and selected pharmacodynamic properties of the histone deacetylase inhibitor depsipeptide in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML).
  • EXPERIMENTAL DESIGN: Depsipeptide was administered to MDS or AML patients at a (solid tumor) phase I dose of 18 mg/m(2) i.v. on days 1 and 5 every 3 weeks.
  • RESULTS: Twelve patients (nine with AML, three with MDS) received one to five cycles of depsipeptide.
  • The best response of 11 assessed patients was one complete remission in a patient with AML, stable disease in six patients, and progression of disease in four patients.
  • Exploratory laboratory studies showed modest but rapid increases in apoptosis and changes in myeloid maturation marker expression.
  • Depsipeptide monotherapy has limited clinical activity in unselected AML/MDS patients.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Depsipeptides / pharmacokinetics. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy


79. Makropoulos V, Alexopoulos EC: Case report: Hydroquinone and/or glutaraldehyde induced acute myeloid leukaemia? J Occup Med Toxicol; 2006;1:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Hydroquinone and/or glutaraldehyde induced acute myeloid leukaemia?
  • BACKGROUND: Exposures to high doses of irradiation, to chemotherapy, benzene, petroleum products, paints, embalming fluids, ethylene oxide, herbicides, pesticides, and smoking have been associated with an increased risk of acute myelogenous leukemia (AML).
  • Although there in no epidemiological evidence of relation between X-ray developer, fixer and replenisher liquids and AML, these included glutaraldehyde which has weakly associated with lymphocytic leukemia in rats and hydroquinone has been increasingly implicated in producing leukemia, causing DNA and chromosomal damage, inhibits topo-isomerase II, alter hematopoiesis and inhibit apoptosis of neoplastic cells.
  • In July 2001, woman A, 38-years-old, was diagnosed as having acute monocytic leukaemia (FAB M5).
  • In August 2001, woman B, 35-year-old, was diagnosed with acute promyelocytic leukaemia (FAB M3).
  • Since discharge, she is in continuous complete remission.
  • Both women were non smokers without any medical history.
  • CONCLUSION: The findings support the hypothesis that the specific AML cases might have originated from exposure to chemicals, especially hydroquinone and/or glutaraldehyde.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 May 1;65(9):3527-30 [15867342.001]
  • [Cites] Toxicol Pathol. 2005;33(4):415-24 [16036858.001]
  • [Cites] Occup Environ Med. 2005 Dec;62(12):861-7 [16299095.001]
  • [Cites] Br J Radiol. 1991 May;64(761):455-60 [2036572.001]
  • [Cites] Toxicol Appl Pharmacol. 1989 Mar 1;97(3):440-53 [2609342.001]
  • [Cites] Australas Radiol. 1986 Aug;30(3):281-6 [3814001.001]
  • [Cites] Ann Occup Hyg. 1993 Jun;37(3):287-95 [8346876.001]
  • [Cites] Br J Ind Med. 1993 Feb;50(2):107-11 [8435342.001]
  • [Cites] Occup Environ Med. 1996 Jul;53(7):450-4 [8704868.001]
  • [Cites] Ann Occup Hyg. 1996 Aug;40(4):423-35 [8806214.001]
  • [Cites] Stem Cells. 1996 Nov;14(6):730-42 [8948030.001]
  • [Cites] Ann Occup Hyg. 1997 Dec;41(6):691-8 [9375527.001]
  • [Cites] Br J Cancer. 1998 Aug;78(3):312-20 [9703276.001]
  • [Cites] Mol Pharmacol. 1999 May;55(5):894-901 [10220568.001]
  • [Cites] J Epidemiol. 1999 Apr;9(2):61-72 [10337078.001]
  • [Cites] Crit Rev Toxicol. 1999 May;29(3):283-330 [10379810.001]
  • [Cites] Exp Hematol. 2000 Feb;28(2):169-76 [10706073.001]
  • [Cites] Occup Med (Lond). 2000 Jan;50(1):39-42 [10795391.001]
  • [Cites] Am J Epidemiol. 2001 Feb 15;153(4):309-18 [11207146.001]
  • [Cites] Leukemia. 2001 Jan;15(1):10-20 [11243376.001]
  • [Cites] Am J Ind Med. 2001 Jul;40(1):3-14 [11439392.001]
  • [Cites] Health Phys. 2002 Apr;82(4):455-66 [11906134.001]
  • [Cites] Am J Ind Med. 2003 Feb;43(2):132-41 [12541267.001]
  • [Cites] Occup Environ Med. 2003 Apr;60(4):254-61 [12660373.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):3080-9 [12784345.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1296-304 [15129224.001]
  • [Cites] Environ Mol Mutagen. 2004;43(4):258-64 [15141365.001]
  • [Cites] Biochim Biophys Acta. 2004 Sep 6;1690(1):11-21 [15337166.001]
  • [Cites] Chem Res Toxicol. 2005 Apr;18(4):761-70 [15833037.001]
  • (PMID = 16872480.001).
  • [ISSN] 1745-6673
  • [Journal-full-title] Journal of occupational medicine and toxicology (London, England)
  • [ISO-abbreviation] J Occup Med Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1544343
  •  go-up   go-down


80. Bacher U, Kern W, Schoch C, Schnittger S, Hiddemann W, Haferlach T: Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer; 2006 Feb 15;106(4):839-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia.
  • BACKGROUND: Different diagnostic methods add information to define complete remission (CR) in patients with acute myeloid leukemia (AML).
  • METHODS: The authors studied 216 patients with AML at the time of initial diagnosis and during follow-up and correlated cytomorphology, interphase fluorescence in situ hybridization (FISH), and flow cytometry results to evaluate response status.
  • RESULTS: Interphase FISH was found to be correlated significantly with the clinical course at the time of complete cytomorphologic remission and was more reliable than morphology for defining CR.
  • CONCLUSIONS: The current results indicated that interphase FISH may be used as a valid MRD parameter in patients with AML.
  • Multiparameter immunophenotyping for MRD also was correlated strongly with the clinical course, and the authors suggest integrating such immunophenotyping into the routine diagnostic panel at the time of diagnosis and during the clinical course in patients with AML.
  • [MeSH-major] In Situ Hybridization, Fluorescence. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Female. Flow Cytometry. Humans. Immunophenotyping. Interphase. Male. Middle Aged. Neoplasm, Residual. Prognosis. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16419072.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


81. Rodriguez V, Anderson PM, Litzow MR, Erlandson L, Trotz BA, Arndt CA, Khan SP, Wiseman GA: Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia. Leuk Lymphoma; 2006 Aug;47(8):1583-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marrow irradiation with high-dose 153Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia.
  • In four patients, aged 15 - 20 years, with high-risk acute myeloid leukemia (AML), high-dose samarium 153-labelled ethylenediaminetetramethylenephosphonate (153Sm-EDTMP) was used for targeted marrow irradiation before preparative chemotherapy conditioning regimens and allogeneic (three patients) or autologous (one patient) hematopoietic stem cell transplantation.
  • Complete cytogenetic and morphologic remission of AML was evident on follow-up marrow aspirate and biopsy specimens from all patients.
  • In two of the four study patients, the disease remains in complete remission and the patients have an excellent quality of life (Eastern Cooperative Oncology Group performance status 0; no medications) and no organ toxicity more than 2 years and more than 4 years, respectively, after their blood and bone marrow transplantations.
  • Thus, in adolescents and adults, 153Sm-EDTMP may provide a relatively simple and effective means for using irradiation to eliminate AML within the marrow.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / radiotherapy. Radioisotopes / therapeutic use. Samarium / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Bone Marrow / radiation effects. Dose-Response Relationship, Radiation. Humans. Organometallic Compounds / administration & dosage. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Quality of Life. Remission Induction / methods. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Samarium, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966270.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 42OD65L39F / Samarium
  •  go-up   go-down


82. Rosenfeld CS: Clinical development of decitabine as a prototype for an epigenetic drug program. Semin Oncol; 2005 Oct;32(5):465-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A clinical development program with low-dose decitabine in malignant diseases is focused on myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML), and chronic myelogenous leukemia (CML).
  • A phase III trial in MDS showed objective responses (complete [CR] plus partial [PR] remission) and longer median time to progression to AML or death with decitabine than with supportive care alone.
  • [MeSH-minor] Antigens, Neoplasm / chemistry. Antineoplastic Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis. Clinical Trials as Topic. DNA Adducts. Enzyme Inhibitors / pharmacology. Gene Expression Regulation, Neoplastic. Gene Silencing. Histone Deacetylase Inhibitors. Humans. Leukemia, Myeloid, Acute / drug therapy. Myelodysplastic Syndromes / drug therapy. Remission Induction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210087.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Number-of-references] 72
  •  go-up   go-down


83. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, Durrant S, Schwarer A, Bardy P, Herrmann R, Dodds A: Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant; 2007 May;13(5):601-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
  • Recent studies have shown comparable survival outcomes for unrelated donor (URD) stem cell transplantation in chronic myelogenous leukemia compared to sibling donors.
  • We compared outcomes for 105 patients aged 16 to 59 years undergoing URD transplants for acute myelogenous leukemia (AML) who were reported to the Australasian Bone Marrow Transplant Recipient Registry between 1992 and 2002, and a strictly selected matching set of 105 HLA-matched sibling donor (MSD) transplants.
  • There was no significant difference between URD and MSD controls in the distributions of time from diagnosis to transplant, donor-recipient sex match, prior therapies, donor age, or performance status.
  • There were 18 good risk (complete remission [CR]1) and 87 poor risk (>CR1) recipients in both URD and sibling groups.
  • There was no difference in the cumulative incidence of acute graft-versus-host disease grade II or above at 100 days.
  • Based on this data, URD allografts should be considered in AML patients without a matched sibling donor.
  • This study provides a rationale for a larger prospective study of risk factors in allogeneic transplantation for AML and a guide on the subset of patients who may most benefit from an unrelated donor allograft in AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448920.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Tsavaris N, Kopterides P, Kosmas C, Siakantaris M, Patsouris E, Pangalis G: Spontaneous remission of acute myeloid leukemia associated with GnRH agonist treatment. Leuk Lymphoma; 2006 Mar;47(3):557-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute myeloid leukemia associated with GnRH agonist treatment.
  • Spontaneous remission of acute myeloid leukemia (AML) in adults is a rare but well documented phenomenon.
  • This study reports on a 64-year-old male patient with acute myelogenous leukemia (AML-M4, according to the French-American-British classification) that was developed on a background of chronic myelomonocytic leukemia (CMML) and then underwent remission after treatment with the gonadotropin-releasing hormone agonist (GnRH agonist) triptorelin for presumed prostate cancer.
  • Remission persisted for at least 4 years before the patient was lost to follow-up.
  • To the author' knowledge, this is the first report of remission in an AML-M4 case associated with hormone manipulation.
  • [MeSH-major] Gonadotropin-Releasing Hormone / agonists. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / pathology. Leukemia, Myelomonocytic, Chronic / drug therapy. Triptorelin Pamoate / therapeutic use
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Middle Aged. Remission, Spontaneous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396781.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


85. Lee J, Kern WF, Cain JB, Mulvihill JJ, Li S: A variant t(8;10;21) in a patient with pathological features mimicking atypical chronic myeloid leukemia. Cancer Genet Cytogenet; 2005 May;159(1):79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant t(8;10;21) in a patient with pathological features mimicking atypical chronic myeloid leukemia.
  • We report the case of an 11-year-old girl who was initially diagnosed with a chronic myeloproliferative disorder, possibly chronic myelogenous leukemia (CML), based on laboratory and blood and marrow morphological findings.
  • The treatment regime was switched to an acute myeloid leukemia (AML) protocol; the patient responded well and is now in remission.
  • This case demonstrates again that routine clinical cytogenetic analysis plays an important role in the clinical diagnosis, guidance of treatment, and prognostication in hematological disorders.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. Genetic Variation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Translocation, Genetic


86. Shipley JL, Butera JN: Acute myelogenous leukemia. Exp Hematol; 2009 Jun;37(6):649-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia.
  • Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions.
  • For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
  • For adults older than 60 years of age, only 40% to 55% achieve a complete remission, with dismal long-term survival rates.
  • Unfortunately, the median age at diagnosis for AML is 70 years.
  • Significant advances in our understanding of the molecular biology of AML have led to newer therapies that specifically target molecular abnormalities.
  • This review summarizes the standard treatments for AML and discusses the role of novel therapies.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463767.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 105
  •  go-up   go-down


87. Kalaycio M, Advani A, Pohlman B, Sekeres M, Tripp B, Rybicki L, Sobecks R: Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. Am J Hematol; 2008 Nov;83(11):831-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
  • Cytogenetic analysis at the time of diagnosis predicts outcome in patients with acute myelogenous leukemia (AML).
  • We treated patients with de novo AML and age less than 60 years first with etoposide, mitoxantrone, cytarabine, and G-CSF (EMA-G) to induce remission.
  • Patients in complete remission were assigned to treatment with chemotherapy alone if they had favorable risk cytogenetics defined as the identification of a core-binding factor translocation.
  • Of the 33 patients in remission, 5 year relapse-free survival (RFS) and overall survival (OS) was 46 and 38%, respectively.
  • Our intensive and risk-adapted, stem cell transplant approach to the treatment of patients with AML requires a better definition of risk and does not appear to substantially improve results compared with more standard approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Chromosome Aberrations / classification. Cohort Studies. Combined Modality Therapy. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Remission Induction / methods

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [CommentIn] Am J Hematol. 2008 Nov;83(11):829-30 [18828158.001]
  • (PMID = 18756545.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


88. Al-Tawfiq JA, Al-Khatti AA: Spontaneous remission of acute monocytic leukemia after infection with Clostridium septicum. Int J Lab Hematol; 2007 Oct;29(5):386-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute monocytic leukemia after infection with Clostridium septicum.
  • Spontaneous remissions of acute myeloid leukemia (AML) have been reported in association with infection.
  • Here, we report a case of spontaneous remission of AML in a 47-year-old Saudi Arabian male patient who presented with a few weeks history of recurrent abdominal pain, vomiting and fever.
  • He was diagnosed with acute monocytic leukemia (AML, FAB M5b) and a perforated bowel.
  • Six weeks later, he achieved spontaneous and complete remission lasting for about 4 months.
  • The remission and relapse were documented by bone marrow examination.
  • Similarly, previous reports of spontaneous remission of AML were short lived and were followed by relapse and progression.
  • [MeSH-major] Clostridium Infections / complications. Clostridium septicum / pathogenicity. Intestinal Perforation / complications. Leukemia, Monocytic, Acute / complications
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824921.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F: Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer; 2009 Jan 1;115(1):101-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.
  • BACKGROUND: Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children.
  • METHODS: A total of 641 patients with de novo ALL who were treated with the hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen or its variants were analyzed.
  • RESULTS: Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients).
  • At the time of ALL diagnosis, the median age was 53 years; cytogenetics were normal in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients.
  • Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients.
  • Secondary AML/MDS developed at a median of 32 months after ALL diagnosis.
  • Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS.
  • Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated.
  • Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation.
  • The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months).
  • CONCLUSIONS: Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / chemically induced. Myelodysplastic Syndromes / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


90. Barrett AJ, Le Blanc K: Immunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol; 2010 Aug;161(2):223-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy prospects for acute myeloid leukaemia.
  • While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML), the disease has a high probability of relapse.
  • Evidence for immunosurveillance of AML and susceptibility of leukaemia cells to both T cell and natural killer (NK) cell attack and justifies the application of immune strategies to control residual AML persisting after remission induction.
  • Immune therapy for AML includes allogeneic stem cell transplantation, adoptive transfer of allogeneic or autologous T cells or NK cells, vaccination with leukaemia cells, dendritic cells, cell lysates, peptides and DNA vaccines and treatment with cytokines, antibodies and immunomodulatory agents.
  • Here we describe what is known about the immunological features of AML at presentation and in remission, the current status of immunotherapy and strategies combining treatment approaches with a view to achieving leukaemia cure.
  • [MeSH-major] Immunotherapy / methods. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):483-4 [18938742.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4934-9 [18591543.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5192-7 [18854573.001]
  • [Cites] Leuk Lymphoma. 2008 Nov;49(11):2187-95 [19021063.001]
  • [Cites] Leukemia. 2009 Jan;23(1):53-8 [18830260.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] Blood. 2009 Jan 22;113(4):875-82 [18922853.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1037-45 [19155305.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2245-55 [18988867.001]
  • [Cites] Blood. 2009 Mar 5;113(10):2312-23 [19074734.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:1761-70 [19273160.001]
  • [Cites] Leukemia. 2009 Mar;23(3):486-91 [19092854.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Apr;15(4):421-31 [19285629.001]
  • [Cites] Oncologist. 2009 Mar;14(3):240-52 [19289488.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jun;58(6):855-65 [18841361.001]
  • [Cites] Leuk Lymphoma. 2009 Mar;50(3):427-36 [19225975.001]
  • [Cites] Leukemia. 2009 Apr;23(4):641-8 [19151770.001]
  • [Cites] Transfusion. 2009 Feb;49(2):362-71 [19389215.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jul;58(7):1047-55 [19018534.001]
  • [Cites] Int J Hematol. 2009 May;89(4):460-9 [19360457.001]
  • [Cites] Cytotherapy. 2009;11(3):341-55 [19308771.001]
  • [Cites] J Immunother. 2009 May;32(4):408-14 [19342964.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4010-7 [19383914.001]
  • [Cites] Leuk Res. 2009 Jul;33(7):948-57 [19233469.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6541-8 [19389880.001]
  • [Cites] Cancer Immunol Immunother. 2009 Oct;58(10):1669-77 [19225777.001]
  • [Cites] Cancer Immunol Immunother. 2009 Oct;58(10):1679-90 [19283381.001]
  • [Cites] Cell. 2009 Jul 23;138(2):286-99 [19632179.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):478-88 [19641204.001]
  • [Cites] Scand J Immunol. 2009 Sep;70(3):194-205 [19703009.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):503-5 [19707241.001]
  • [Cites] Blood. 2009 Aug 27;114(9):1736-45 [19556425.001]
  • [Cites] Cytotherapy. 2009;11(5):653-68 [19530029.001]
  • [Cites] Expert Rev Vaccines. 2009 Oct;8(10):1415-25 [19803762.001]
  • [Cites] Curr Opin Immunol. 2009 Oct;21(5):525-30 [19717293.001]
  • [Cites] Br J Haematol. 2010 Mar;148(6):879-89 [20064159.001]
  • [Cites] Haematologica. 2010 Jul;95(7):1191-7 [20081055.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1653-61 [17145602.001]
  • [Cites] Cytotherapy. 2006;8(6):554-8 [17148031.001]
  • [Cites] Clin Exp Immunol. 2007 May;148(2):189-98 [17437417.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):186-95 [17593025.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2145-52 [17673900.001]
  • [Cites] Front Biosci. 2008;13:2022-9 [17981688.001]
  • [Cites] Leuk Res. 2008 Dec;32(12):1842-8 [18614230.001]
  • [Cites] Eur J Haematol. 2008 Oct;81(4):281-8 [18573171.001]
  • [Cites] Int J Lab Hematol. 2008 Oct;30(5):372-81 [18205840.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jan-Feb;40(1):113-6 [17855129.001]
  • [Cites] Blood. 2008 Jan 1;111(1):236-42 [17875804.001]
  • [Cites] Ann Oncol. 2008 Jan;19(1):128-34 [17906298.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):407-15 [18058809.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):486-94 [18249062.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3633-43 [10572074.001]
  • [Cites] Exp Hematol. 2001 Jun;29(6):709-19 [11378266.001]
  • [Cites] Cancer Immunol Immunother. 2001 Jun;50(4):173-80 [11459169.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3750-6 [11739182.001]
  • [Cites] Clin Exp Immunol. 2001 Dec;126(3):403-11 [11737054.001]
  • [Cites] Leuk Res. 2002 Apr;26(4):383-9 [11839382.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4343-9 [12036860.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2075-82 [12533031.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):442-51 [12580958.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1481-7 [12627513.001]
  • [Cites] Leukemia. 2003 Apr;17(4):716-30 [12682629.001]
  • [Cites] Adv Cancer Res. 2003;90:127-56 [14710949.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):265-72 [322689.001]
  • [Cites] Nat Immun Cell Growth Regul. 1983-1984;3(4):165-80 [6597341.001]
  • [Cites] Blood. 1986 Nov;68(5):1030-5 [3768529.001]
  • [Cites] Semin Hematol. 1987 Jan;24(1):40-54 [3547672.001]
  • [Cites] Leuk Res. 1990;14(11-12):967-73 [2280612.001]
  • [Cites] Br J Haematol. 1991 Jan;77(1):43-9 [1998596.001]
  • [Cites] Am J Hematol. 1991 Jun;37(2):88-99 [2069169.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2158-63 [7919330.001]
  • [Cites] Cell. 1995 Apr 7;81(1):9-12 [7536631.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(9):891-7 [9156262.001]
  • [Cites] Bone Marrow Transplant. 1997 May;19(10):989-99 [9169643.001]
  • [Cites] Leukemia. 1998 Jan;12(1):52-8 [9436920.001]
  • [Cites] Scand J Immunol. 1998 Jan;47(1):54-62 [9467659.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):914-9 [9508173.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8639-44 [10411928.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2002-7 [15470487.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1768-73 [16079891.001]
  • [Cites] Eur J Haematol. 2005 Dec;75(6):468-76 [16313258.001]
  • [Cites] Br J Haematol. 2006 Apr;133(2):152-7 [16611305.001]
  • [Cites] Leukemia. 2006 Jan;20(1):29-34 [16281063.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jan;59(1):35-46 [19449004.001]
  • [Cites] Cancer Immunol Immunother. 2010 Jan;59(1):73-9 [19526239.001]
  • [Cites] Curr Gene Ther. 2009 Oct;9(5):396-408 [19860654.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3909-16 [19710498.001]
  • [Cites] Blood. 2009 Oct 29;114(18):3793-802 [19724059.001]
  • [Cites] Leukemia. 2009 Nov;23(11):2109-17 [19626050.001]
  • [Cites] Haematologica. 2010 Jan;95(1):71-8 [19648166.001]
  • [Cites] J Immunol. 2010 Feb 15;184(4):1885-96 [20089697.001]
  • [Cites] Haematologica. 2010 Mar;95(3):485-93 [19903675.001]
  • [Cites] Exp Hematol. 2008 Apr;36(4):451-63 [18261837.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2542-53 [18240144.001]
  • [Cites] Semin Hematol. 2008 Apr;45(2):104-9 [18381105.001]
  • [Cites] J Cell Mol Med. 2008 Jun;12(3):889-98 [18494931.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2222-7 [18688847.001]
  • [Cites] Best Pract Res Clin Haematol. 2008 Sep;21(3):521-41 [18790453.001]
  • [Cites] Mol Cancer Ther. 2008 Sep;7(9):2924-32 [18790773.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):771-7 [18756547.001]
  • [Cites] Br J Haematol. 2008 Sep;142(6):877-88 [18564358.001]
  • (PMID = 20529084.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 108
  • [Other-IDs] NLM/ PMC2909404
  •  go-up   go-down


91. Tallman MS, Pérez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, Bishop MR, Christiansen N, Frankel SR, García JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, Horowitz MM: Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant; 2006 Feb;12(2):204-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
  • Controversy exists over whether pretransplantation consolidation chemotherapy affects the outcome of subsequent autotransplantation for acute myelogenous leukemia (AML).
  • The current study was undertaken to determine the association between previous consolidation and outcome of autotransplantation for AML in first remission.
  • Five-year leukemia-free survival rates were 39% (95% CI = 30%-47%) with no consolidation, 53% (95% CI = 46%-60%) with standard-dose cytarabine, and 48% (95% CI = 40%-56%) with high-dose cytarabine (P = .03).
  • Based on our findings, we recommend that patients with AML in first remission receive consolidation before undergoing autotransplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation / mortality. Leukemia, Myeloid, Acute / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443518.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R: Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol; 2006 Jan 20;24(3):444-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
  • The study reported here assessed outcomes for patients with acute myeloid leukemia (AML) in different stages of their disease, who were not considered candidates for conventional hematopoietic cell transplantation (HCT) because of age and/or other known risk factors and were given minimal conditioning followed by HCT from related or unrelated donors.
  • PATIENTS AND METHODS: The present study included 122 patients with AML, who were conditioned with 2 Gy total-body irradiation (TBI) on day 0 with or without preceding fludarabine (30 mg/m2/d from days -4 to -2), and given postgrafting cyclosporine at 6.25 mg/kg twice daily from day -3 and mycophenolate mofetil at 15 mg/kg twice daily from day 0.
  • Cumulative incidences of acute graft-versus-host disease grades 2 to 4 at 6 months were 35% after related and 42% after unrelated HCT, respectively.
  • With a median follow-up of 44 months (range, 26 to 79 months), 51 patients were alive, of whom 48 were in complete remission (CR).
  • CONCLUSION: We conclude that HCT from related and unrelated donors after low-dose TBI is a promising treatment for elderly patients with AML.


93. Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA: A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect; 2007 Nov;55(5):445-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
  • We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML).
  • METHODS: This was a prospective, randomised, double-blind, placebo-controlled phase III trial in AML patients undergoing remission induction chemotherapy.
  • CONCLUSION: In AML patients undergoing induction chemotherapy, prophylactic oral voriconazole 200 mg twice daily resulted in trends towards reduced incidences of lung infiltrates and hepatosplenic candidiasis.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Lung Diseases, Fungal / prevention & control. Mycoses / prevention & control. Pyrimidines / adverse effects. Pyrimidines / therapeutic use. Triazoles / adverse effects. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822770.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Placebos; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


94. Callera F, Mulin CC, Rosa ES, Melo DB, Melo CM: High prevalence of morphological subtype FAB M1 in adults with de novo acute myeloid leukemia in São José dos Campos, São Paulo. Sao Paulo Med J; 2006 Jan 5;124(1):45-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of morphological subtype FAB M1 in adults with de novo acute myeloid leukemia in São José dos Campos, São Paulo.
  • CONTEXT AND OBJECTIVE: Geographical variations have been described in acute myelogenous leukemia (AML).
  • The aim of this study was to demonstrate the high prevalence of French-American-British (FAB) M1 subtype in adults with de novo AML in São José dos Campos, State of São Paulo, Brazil.
  • DESIGN AND SETTING: Retrospective analysis, at Hospital Pio XII in São José dos Campos, a public non-teaching institution.
  • METHODS: Records from 39 consecutive adult patients with de novo AML referred to Hospital Pio XII between January 2002 and September 2004 were reviewed.
  • The rates of remission, relapse, mortality according treatment phase, survival and leukemia-free survival were calculated.
  • The remission and the relapse rates were 82% and 41% respectively.
  • The mortality rate was 69% (induction of remission: 7/39, 17.9%; post induction: 10/32, 31.2%; and relapse: 10/16, 62.5%).
  • The survival rate was 30% and leukemia-free survival was 33%.
  • CONCLUSIONS: The study demonstrated a high prevalence of FAB M1 subtype in adults with de novo AML in São José dos Campos.
  • Our data suggest the occurrence of different regional prevalences of FAB AML categories in Brazil.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612463.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


95. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE: Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant; 2008 Jun;14(6):672-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.
  • To account for improved supportive care and other unidentified factors that may affect outcome ("period" effects), 78 acute myelogenous leukemia (AML) patients receiving Melphalan-Flu (MF), treated in parallel during this time (1997-2004) were used to estimate the period effect.
  • Patients transplanted with Bu-Flu in the first complete remission (CR1) had a 3-year overall survival and event-free-survival (EFS) of 78% and 74%, respectively, whereas CR1 patients younger than age 41 had a 3-year EFS of 83%.
  • These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489993.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / 2P01 CA55164; United States / NCI NIH HHS / CA / P01 CA055164-160020; United States / NCI NIH HHS / CA / 2P30CA16672-26; United States / NCI NIH HHS / CA / P01 CA055164
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Antineoplastic Agents; 0 / Myeloablative Agonists; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS52878; NLM/ PMC4230823
  •  go-up   go-down


96. Medeiros BC, Minden MD, Schuh AC, Schimmer AD, Yee K, Lipton JH, Messner HA, Gupta V, Chun K, Xu W, Das P, Kamel-Reid S, Brandwein JM: Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (&gt;5 years). Leuk Lymphoma; 2007 Jan;48(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).
  • The clinical characteristics and outcome of 15 patients with acute myelogenous leukemia (AML) who experienced relapse at least 5 years after induction of complete remission (very late-relapse AML) are described.
  • There were eight males in this cohort and the median age at diagnosis was 48 years (range 13 - 77 years).
  • The median duration of first complete remission (CR-1) was 9 years (range 5.2 - 11.5 years).
  • We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Remission Induction. Retrospective Studies. Survival Analysis


97. Liu Y, Ke XY, Ma J, Shen ZX, Zhang XH, Du X, Zhao YM, Lv JQ, Zhan ZM, Zeng XY, Xu XH, Lu ZS: [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):706-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
  • OBJECTIVE: To evaluate the safety of domestically produced idarubicin in the treatment of acute leukemia by a multicenter randomized control trial.
  • METHODS: This trial was carried out in the hemotologica department of five hospitals throughout China, with hospitalized patients who suffered from acute myelogenous leukemia ( AML except M3 type) , acute lymphocytic leukemia ( ALL) , chronic myelogenous leukemia-blast (CML-blast) , totally 155 patients.
  • In this study, 155 leukemia patients were randomly grouped into: 1. test group treated using domestic idarubicin, 2. control group using imported idarubicin.
  • The acute myelogenous leukemia regimen included idarubicin 8 mg/m(2), dl -3 plus cytosine arabinoside 100 mg/m(2), dl - 7 for 1-2 cycles.
  • The regimen for acute lymphocytic leukemia was idarubicin 8 mg/m2, dl - 3; vincristine 2 mg/mr, dl; cyclophosphamide 750 mg/m2, dl ; plus prednisone 60 mg/m(2),dl - 14 for 1-2 cycles.
  • The incidence of non-hematological toxicities in domestic idarubicin group and imported idarubicin group was 84.
  • Discontinuation of treatment due to non-hematological toxicity was not neccessary.
  • CONCLUSION: Domestic idarubicin is comparable to imported counterpart in efficiency and safety for the treatment of acute leukemia.
  • The most severe side effects of domestic idarubicin is hematological toxicity, which should be closely observed and treated in time, while its non-hematological toxicity is tolerable.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Agranulocytosis / chemically induced. Blast Crisis / drug therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Female. Humans. Male. Middle Aged. Mucositis / chemically induced. Nausea / chemically induced. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274381.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


98. Zhang YL, Ren JH, Guo XN, Zhang JN, Wang Y, Qiao SK, Lin FR: [Expression of c-fes gene in leukemia cells and its clinical significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1429-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of c-fes gene in leukemia cells and its clinical significance].
  • This study was purposed to investigate the expression of c-fes gene in leukemia patients and its clinical significance.
  • The expression of c-fes mRNA in bone marrow cells from 121 cases of acute and chronic leukemia patients, and the expression of c-fes mRNA in peripheral blood mononuclear cells of 20 normal persons were detected by real time-quantitative reverse transcription polymerase chain reaction (RQ-PCR).
  • The results showed that the level of c-fes mRNA in AML patients was higher than that in normal controls [(48.017 +/- 57.170) x 10(-3) vs (0.152 +/- 0.398) x 10(-3)] (p < 0.0001); but there was no significant differences of level of c-fes mRNA between samples of ALL and normal controls(0.047 +/- 0.068) x 10(-3) vs(0.152 +/- 0.398) x 10(-3) (p>0.05); the level of c-fes mRNA in CML patients was higher than that in normal persons (21.605 +/- 24.818) x 10(-3) vs (0.152 +/- 0.398) x 10(-3) (p < 0.0001).
  • In AML patients, c-fes gene was expressed higher in M(2) (80.77%) and M(3) (92.86%) patients.
  • The remission rate of AML (except M(3))patients who had expression of c-fes gene was 81.08%, which was higher than that of patients with no expression of c-fes gene (40.00%).
  • It is concluded that c-fes gene expression was found in myeloid leukemias, whereas low or no expression in lymphocytic leukemias.
  • The differentiation of myelocytic cells may be related to c-fes gene.
  • All AML (except M(3))patients with high level of c-fes mRNA may get good prognosis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030920.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.7.10.2 / FES protein, human; EC 2.7.10.2 / Proto-Oncogene Proteins c-fes
  •  go-up   go-down


99. Katsuya H, Takata T, Ishikawa T, Sasaki H, Ishitsuka K, Takamatsu Y, Tamura K: A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant Bacillus cereus. J Infect Chemother; 2009 Feb;15(1):39-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant Bacillus cereus.
  • We report a case of fatal pneumonia caused by B. cereus in a patient with newly diagnosed acute myeloid leukemia (AML) during remission induction therapy.
  • [MeSH-major] Bacillaceae Infections / microbiology. Bacillus cereus / drug effects. Carbapenems / pharmacology. Leukemia, Myeloid, Acute / complications. Pneumonia, Bacterial / microbiology. beta-Lactam Resistance
  • [MeSH-minor] Anti-Bacterial Agents / pharmacology. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Immunocompromised Host. Lung / radiography. Male. Middle Aged. Neutropenia. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280299.001).
  • [ISSN] 1341-321X
  • [Journal-full-title] Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
  • [ISO-abbreviation] J. Infect. Chemother.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Carbapenems
  •  go-up   go-down


100. Brkljacic B, Cikara I, Ivanac G, Hrkac Pustahija A, Zic R, Stanec Z: Ultrasound-guided bipolar radiofrequency ablation of breast cancer in inoperable patients: a pilot study. Ultraschall Med; 2010 Apr;31(2):156-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were at high-risk for general anesthesia and surgery because of severely impaired cardiac function, advanced age, or associated diseases (acute myeloid leukaemia (AML), diabetes, hypertension, depression) and/or refused surgery.
  • The Patient with AML and BCA had an infection of the treated breast after 4 months and postponed mastectomy to an AML remission status.
  • There were no signs of malignancy in histopathology; the patient finally died of leukemia 42 months after RFA.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 19941254.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down